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Summary 
Introduction 
The emergence of evidenced-based medicine (EBM) has led to an ever-increasing 
plethora of guidelines to follow in order to best deliver this high standard of 
care.  Compliance with such guidelines remains sub-optimal and novel methods 
of guideline dissemination have become popular.  
Two patient safety areas of major morbidity and, potentially, mortality for 
patients are venous thromboembolism (VTE) and sepsis. Prophylaxis is available 
to minimise risk of VTE and early resuscitation bundles for sepsis, such as Sepsis 
Six have become widely promoted. Both of these areas have local guidelines that 
should be followed but compliance is poor.  At the start of this period of 
research Sepsis Six had not yet been rolled-out in the surgical department at the 
RAH, Paisley.  This provided a golden opportunity to look at guideline 
dissemination for one area, using a variety of modalities. 
Smartphone technology has become ubiquitous in the past few years.  The 
reasons for this are examined and the role for smartphones, and their 
applications (apps) in delivering assistance to doctors involved in front-line care 
is discussed.  Potential regulatory issues are reviewed  
Aims 
The aims of this thesis are: 
To assess prevalence of smartphones in the doctor population in a three-site 
hospital board area and these doctors’ attitudes to smartphone technology for 
clinical uses. 
To design and implement novel apps for thromboprophylaxis and Sepsis Six as a 
supplemental modality for guideline dissemination. 
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To assess the impact of the introduction of these apps on guideline compliance, 
including assessing for fatiguing of interest. 
Materials and Methods 
A SurveyMonkey questionnaire was emailed to all 456 doctors across the three 
hospitals in the GGC Clyde sector asking about smartphone ownership and usage 
and their views on the roles of apps for clinical care. 
Native smartphone apps were designed and developed for both iPhone and 
android platforms for both VTE prophylaxis and Sepsis Six. Once these had been 
field-tested, and pre-app audit of current guideline compliance undertaken they 
were manually deployed to the surgical junior doctors at the Royal Alexandra 
Hospital, Paisley.  Concurrently, while the Sepsis Six app was being developed 
the concept of Sepsis Six was rolled out using standard posters, presentations 
and tutorials. 
After each modality introduction for both VTE prophylaxis and Sepsis Six audit 
was undertaken both early, and some time later, to try and assess possible 
fatiguing of interest and compliance. 
Results 
There was a good response to the survey, revealing very high smartphone 
ownership levels at virtually 90%, with 100% ownership in doctors in the early 
years of training.  Further analysis revealed that doctors in the middle of their 
training, rather than at either extreme, were the most likely to use a 
smartphone for clinical care.  Doctors preferentially own iPhones rather than 
Android based smartphones which is out-of-keeping with worldwide, and indeed 
UK statistics, strongly favouring Android. 
VTE prophylaxis at baseline audit was better than expected. This meant it was 
difficult to show any improvement on addition of the smartphone app. There 
were transient improvements in the correct prescribing of anti-embolic stockings 
however but generally results suggested that the app simply wasn’t being used. 
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Sepsis bundle compliance at baseline was poor but slowly improved over the 
seven audit points. There were no sharp improvements in Sepsis Six bundle 
compliance to suggest that either the traditional methods or the app were 
particularly good at improving guideline compliance. 
Conclusions 
Electronic patient care is fast becoming universal and smartphone/ tablet 
technology will be at the forefront of this.  Despite disappointing results here, 
the use of an app for more complex patient-specific guidelines is likely to 
become increasingly popular, as long as accuracy of the information provided by 
the app can be guaranteed. 
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1 Introduction 
 Background 1.1
 Guidelines in Medicine and Surgery 1.1.1
Provenance and Types of Guidelines 
Healthcare guidelines have been described as "systematically developed 
statements to assist practitioner and patient decisions about appropriate health 
care for specific clinical circumstances."  (2) 
Over the past few years there has been increasing awareness of the importance 
of Evidence-Based Medicine (EBM) in patient care.  In order to best deliver EBM 
to patients, guidelines and protocols have been developed to facilitate this – the 
most well-known bodies (in the United Kingdom) developing these being the 
Scottish Intercollegiate Guidelines Network (SIGN)  (1) and the National Institute 
for Health and Care Excellence (NICE)  (3).  SIGN guidelines are developed by 
interested and respected clinicians and associated healthcare professionals 
across Scotland.  They are updated every 3-7 years and each time a full 
systematic review of the existing literature is undertaken by the specialist 
panel. 
These national guidelines grade their recommendations based on the quality and 
strength of the evidence reviewed.  Therefore grade “A” recommendations are 
not more important than grade “D” ones, merely that the weight of evidence 
behind grade “A” is greater (Appendix 3). 
Methods of guideline dissemination and barriers to compliance 
Guidelines require dissemination in order to be used.  Traditionally this has been 
via hard-copy: posters, hand-outs, journals; moving towards pocket hand-books; 
then to virtual platforms such as inter-and intra-net accessibility and, latterly, 
to mobile device technology (4). 
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It is logical that well-implemented healthcare-related guidelines should improve 
quality of patient care provided, by minimising procedural variation and 
promoting the provision of evidenced-based best practice.  However, despite 
best efforts, compliance with and uptake of guidelines remains patchy (5), (6). 
There has been much interest in motivators and barriers to compliance.  Various 
factors have been identified that are barriers to guideline compliance and 
adherence (7).  These include systems ambiguity (8), behavioural factors (9), 
(10), (11), institutional and environmental factors (12), (7), and guideline-
related factors (13). 
Systematic review has shown it is possible to change healthcare provider 
behaviour, with median absolute percentage improvement of about 10% in 
process-of-care indicators (14).  This does not seem to be dependent on the 
modality of guideline dissemination but perhaps more on having a clear 
consensus from all senior clinicians, good leadership, and direct motivation for 
adherence to a specific set of guidelines (15). 
 Thromboprophylaxis 1.1.2
Context 
Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the 
flow of blood through the circulatory system.  A clot that forms in a leg vein is 
called a Deep Vein Thrombosis (DVT). If it breaks free and begins to travel 
around the body is known as an embolus; an embolus lodging in the lung 
circulation it is called a pulmonary embolism (PE).  In general this process is 
known as venous thrombo-embolism (VTE). 
The risk of VTE is significantly increased in patients who are hospitalised after 
trauma, surgery or immobilising medical illness.  Many of these patients have an 
asymptomatic DVT, but others can suffer considerable morbidity and/or 
mortality.  Successive studies have shown figures as high as 10% of hospital 
deaths (1% of all admissions) attributable to PE in the UK (16), and in 2009 the 
English Department of Health stated that PE caused more than 25,000 
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preventable deaths per year in England and Wales (17).  More recently there has 
been work published suggesting that the rate of autopsy detected PE has 
substantially decreased and may be now in the region of 2% of hospital deaths 
(18).  There are two possible interpretations of this significant drop in PE 
detection: firstly that thromboprophylaxis really is efficacious; secondly that 
patients are being mobilised sooner and being discharged earlier – meaning VTE 
is becoming a post-discharge problem, particularly as the risk of VTE exists for 
up to 90 days after admission.  Either way, the importance of 
thromboprophylaxis cannot be emphasised enough. 
Even non-fatal PE has major consequences, potentially giving rise to significant 
cardio-respiratory embarrassment acutely, as well as chronic pulmonary 
hypertension (19).  The problem is not limited to the embolic component of the 
clot.  Significant morbidity can affect up to 30% of patients after lower limb 
DVT.  This post-thrombotic leg syndrome manifests as chronic leg pain, swelling 
and dermatitis and is a consequence of damage to the valves of the deep veins.  
Chronic venous leg ulcers can also occur in 2-10% of patients in the years 
following their DVT (20), (21), (22). 
The crux of the problem, however, is that potentially fatal PE often results from 
an asymptomatic DVT (23); indeed up to 80% of patients may have a clinically 
silent DVT.  On this basis, thromboprophylaxis is indicated for the majority of 
acutely admitted surgical and medical patients.   
Methods of Thromboprophylaxis 
Thromboprophylaxis can be undertaken using both mechanical and 
pharmacological methods 
Pharmacological thromboprophylaxis 
In recent years low-molecular weight heparin (LMWH) has emerged as the most-
used pharmacological method of preventing VTE.  This is given as a single 
subcutaneous bolus of 0.2 - 0.4 millilitres (volume depending on exact dose and 
brand of LMWH), once daily.  Previously unfractionated heparin (UFH) was 
utilised but this had the significant drawbacks of being a continuous infusion, 
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and the requirement for regular blood test monitoring and dose adjustments 
depending on the results of these coagulation studies.  Many studies (including a 
number of meta-analyses) over the past twenty years have compared LMWH 
against UFH.  These have almost universally endorsed LMWH in preference to 
UFH both in terms of efficacy, ease of administration and monitoring, and side-
effect profile (24),  (25), (26), (27), (28). 
Mechanical thromboprophylaxis 
This can be provided simply, in the ward environment, by applying graduated 
compression stockings (also known as anti-embolism stockings (AES)), or in the 
operating theatre environment or critical care area using intermittent pneumatic 
compression (IPC).   
AES can be knee- or thigh-length and require dimensions of a patient’s leg to be 
measured and the correct size chosen.  This service can be provided by all 
grades of healthcare staff, once they have been appropriately trained.  AES have 
been well validated in their usefulness and even have their own Cochrane 
Review confirming their importance in VTE prevention (29).  They are cheap to 
supply and have few side-effects – however by their very nature, they are 
contraindicated in patients in whom it would be detrimental to apply pressure to 
their legs – such as those with peripheral neuropathy or leg deformities.   
IPC uses an inflatable sleeve that is wrapped around the lower leg and secured 
with Velcro.  Tubing connects the sleeve to an air pump that forces air into the 
sleeve chambers, putting pressure on the soft tissues and forcing blood out of 
the peripheral deep veins and back towards the heart.  Shortly thereafter air 
pumping ceases, air is allowed to exit the sleeve chambers and the deep veins 
can fill again.  The cycle then repeats. 
Overall recommendations 
Across Scotland, SIGN 122 is the Gold standard guideline for both 
thromboprophylaxis and also treatment of VTE.  This recommends: 
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• all patients admitted to hospital or presenting acutely to hospital should 
be individually assessed for risk of VTE and bleeding.  The risks and 
benefits of prophylaxis should be discussed with the patient. 
• the use of a risk assessment method checklist is recommended for this 
purpose).  (see Appendix 2) 
• the assessment should be repeated regularly and at least every 48 hours. 
SIGN 122 also gives a Grade A recommendation that “Patients undergoing 
abdominal surgery who are at risk due to the procedure or personal risk factors 
should receive thromboprophylaxis with mechanical methods unless 
contraindicated and either subcutaneous LMWH, unfractionated heparin or 
fondaparinux”  (16). 
SIGN 122 was developed from many sources across many surgical sub-specialties 
(30), (31) including the 2004 Cochrane Review of thromboprophylaxis in 
colorectal surgery.  This Cochrane review demonstrated that graduated 
compression stockings together with heparin provide optimal prophylaxis (32). 
Available Guidelines 
SIGN 122 was distilled into a flow-chart for the acute medical wards in 2011.  
This was incorporated directly into the Acute Medical Admissions Proforma in 
2011 in order that it became a routine part of admission review and prescribing, 
as indicated.  It was, however, quite convoluted and unwieldy (Appendix 2).  It 
also was not utilised by the surgical directorate who, until late 2013 did not have 
any form of Acute Surgical Admissions Proforma.  Instead, the Greater Glasgow 
& Clyde Health Board (GGC) thromboprophylaxis guidelines were available in the 
GGC Prescribing Handbook (updated yearly and given to all doctors at hospital 
induction as a hard copy), web-based guidelines on the intranet, and posters in 
the wards’ doctors’ rooms. 
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Guideline Compliance 
Successive bi-annual audit cycles looking at thromboprophylaxis at RAH (in-house 
data, not externally presented or published) showed compliance of only 75% for 
this process, using the existing guideline modalities.  These local results 
correlate with national recognition of incomplete implementation of the 
thromboprophylaxis recommendations (33), (34).  Locally, barriers to use of the 
current modalities were reported as being due to inability to access the 
guidelines electronically due to lack of computers and the Handbook being to 
large to carry around and not being available in the most current version in 
clinical areas.   
A review of the literature conducted by SIGN concluded that a passive approach 
to dissemination of these VTE guidelines was inadequate and an active approach 
was required to improve compliance (35).  Novel approaches, such as electronic 
alerts were shown to improve guideline compliance and reduce the burden of 
VTE in a randomised study (36). 
The summary recommendation from SIGN 122 to improve thromboprophylaxis 
guideline compliance is that “hospitals should adopt approaches which are likely 
to increase compliance with thromboprophylaxis guidelines and improve patient 
outcomes”. 
 Sepsis 1.1.3
Pathophysiology of Sepsis 
Sepsis results from activation of the systemic inflammatory response by infection 
(see Appendix 5).  It was first defined in 1991, when the cascade from systemic 
inflammatory response syndrome (SIRS) to sepsis, severe sepsis and ultimately 
septic shock was first outlined at the American College of Chest Physicians 
/Society of Critical Care Medicine Consensus Conference (37).  This strict 
definition of sepsis was revisited again in 2001 by these groups and confirmed as 
two or more features of SIRS plus infection (either confirmed or strongly 
suspected)  (38), with infection being defined as ”a pathological process caused 
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by invasion of normally sterile tissue or fluid or body cavity by pathogenic or 
potentially pathogenic micro-organisms”  (38). 
Global Context 
In the European Union it has been estimated that there are over 90 cases of 
severe sepsis per 100,000 people; in comparison, estimates are that only 58 
people are affected by breast cancer per 100,000  (39).  Mortality for severe 
sepsis is approximately 35% in developed countries, meaning the healthcare 
burden is significant and may result in up to 64,000 deaths yearly in the UK (40).  
Despite all of this, sepsis is frequently overlooked and its consequences 
underestimated.  Recognised early, and with timely intervention, sepsis need 
not be fatal; however, left unchecked, the sepsis cascade can rapidly spiral 
towards septic shock.  The longer the patient is untreated or sub-optimally 
treated, the slimmer the chance of survival – mortality from sepsis is estimated 
at 14%, with severe sepsis this rises to 44% and reaches 58% if septic shock is 
present. 
Surviving Sepsis Campaign 
In 2003, key members of the sepsis working parties from 1991 and 2001 met 
again and the “Surviving Sepsis” campaign was born  (41).  This aimed to identify 
and deliver a bundle of care to critically ill patients before they left the 
Emergency Department.  This was slow to be implemented across the UK but 
updated guidelines published in 2008 were seized upon and strongly promoted 
nationwide  (42).  There were two arms to the 2008 guidelines: a 6-hour 
resuscitation bundle, aiming to reduce sepsis-induced hypoperfusion (Appendix 
6), and a 24-hour “early goal-directed therapy” (EGDT) bundle, mainly involving 
interventions and monitoring in the intensive care setting, based on the work by 
Rivers et al  (43).  These EGDT bundles were all based on sound evidence but 
were over-complicated, quite labour-intensive to deliver and required specialist 
expertise for some tasks.  Overall, it was difficult to achieve EGDT bundle 
compliance in an average non-specialist department  (44).  In a specialised unit, 
however, evaluation of implementation of the 6-hour resuscitation bundle did 
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show improvement in 28-day mortality, but uptake of and compliance with even 
these relatively straight-forward guidelines remained poor  (45). 
It was quickly appreciated that a different approach was needed – to make a 
rapid, reproducible management bundle that would be easy accessible to the 
inexperienced junior doctor on the front line.  The existing sepsis guidelines 
were simplified and condensed, concentrating on the basics – leading to the 
development of Sepsis Six (46).  Patient safety bodies have been quick to back 
this movement and it is now a key tenet of the Scottish Patient Safety 
Programme (SPSP) (47) with Government support and endorsement. 
Identification of Sepsis 
The pathway to a patient being identified as being septic is usually as follows: 
• National Early Warning Score (NEWS) of >4 (Appendix 7) noted during 
observations taken by nursing staff 
• If infection documented or likely, assessed for SIRS (Appendix 5) 
• If SIRS ≥2, sepsis is likely 
On identification of a patient with sepsis, the following package Sepsis Six 
package should be delivered, ideally within one hour: 
• Oxygen to achieve Saturations >94%, ≤ 98% (Caution COPD) 
• IV fluids (≥500ml/hr or 20ml/kg immediately, if organ dysfunction)  
• Blood Cultures 
• Intravenous antibiotics as per local guidelines 
• Measure Lactate and FBC 
• Accurate urine output and catheterise if organ dysfunction 
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Local Context 
Sepsis Six was introduced across GGC from January 2012.  At RAH this was 
initially just in the medical directorate for acute medical admissions.  By August 
2012 this had been firmly established and shown to be of clinical benefit but had 
yet to be rolled-out across the surgical directorate.  This provided the perfect 
opportunity to look at the introduction of a new set of guidelines right from the 
outset (Time Zero). 
Acute medical receiving at RAH is spearheaded by a team of Acute Physicians 
who support all SPSP activities but each have a mandate for one area.  The 
introduction of Sepsis Six was instigated and managed by a newly appointed 
Acute Physician.  He started by concentrating on implementing Sepsis Six in the 
Medical Assessment Unit (MAU) and the Acute Medical Unit (AMU).  However, 
these units functioned in very distinct ways from each other. 
Medical Assessment Unit 
The MAU was open from 10:00-22:00hrs seven days a week, had a maximum 
capacity of eleven patients and had a higher than normal staffing ratio of senior 
nurses and several healthcare assistants.  They took patients who had been 
referred by their General Practitioners (GPs).  On arrival a patient was put 
straight into a cubicle, observations taken within five minutes and the history 
quickly re-visited.  If the NEWS score was >5 and the senior nurse thought the 
patient had an infective pathology, the patient was scored for SIRS and the 
Sepsis Six pathway was triggered – a Sepsis Six sticker (Appendix 10) was placed 
in the patient’s case sheet and an egg-timer was activated with a one-hour 
countdown.  The Sepsis Six trolley was brought to the patient’s cubicle: this 
contained all equipment required to deliver Sepsis Six.  An intravenous cannula 
was placed immediately and blood withdrawn for standard bloods, blood 
cultures and a venous blood gas (for a lactate level).  A 500ml bag of saline or 
Hartmann’s solution was then connected up and run in over roughly thirty 
minutes.  Simultaneously, oxygen was provided to the patient, if required, to 
ensure oxygen saturations were maintained at ≥94%.  The nurse then had the 
patient reviewed by a junior doctor (who was resident in the MAU) who 
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confirmed (or refuted) the diagnosis of likely sepsis and, after determining the 
most likely source of infection, prescribed a first dose of intravenous antibiotics.  
This took merely a few minutes to be made up and was administered through the 
cannula.  Bottles or shells were provided for the patient to pass urine into to 
measure the urine output non-invasively.  If the patient’s physiology suggested 
great cause for concern, a urinary catheter was placed into the bladder instead.  
In September 2012 the average time for this entire process was fifty-seven 
minutes and had fallen further to just twenty minutes by August 2013; well-
within the recommended one hour for delivery of the Sepsis Six package. 
Acute Medical Unit 
The AMU was, in contrast, a standard medical receiving unit.  It operated 
twenty-four hours a day and received all emergency admissions that came via 
the Emergency Department (ED), GP referrals outwith the hours operated by the 
MAU and GP referrals when the MAU was full.  While it was appropriately 
staffed, it was a busy ward with high turnover of patients and many ill patients 
requiring a high level of nursing input.  If a patient triggered a NEWS score of 
greater than 4 and infection thought likely, the Sepsis Six alert was triggered in 
the same way as in MAU.  While an identical set of events, in the same speedy 
fashion, should have taken place as in MAU, this did not occur every time.  Staff 
preoccupation (both nursing and medical) with other ill patients sometimes 
competed with new Sepsis Six triggering patients. 
It was the AMU set-up that was most similar to that of the acute surgical 
receiving ward at RAH. 
There were, however, a number of motivational strategies that the Acute 
Physician employed to keep his team focussed on delivering the Sepsis Six 
package in AMU within the recommended hour.  These included a wallchart of 
fastest implementers per month, with a small prize for the fastest; daily pep-
talks to the AMU team and positive feedback to those completing within the 
hour.  He also undertook weekly review of all patients who had triggered a NEWS 
of 4 or more to see if they should have received the Sepsis Six package and, if 
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they didn’t, why this didn’t happen and what could be done to improve the 
process. 
Sepsis Six in Surgery 
As of August 2012 the pathway for a surgical patient being admitted as an 
emergency was this:  
All patients (GP and ED referrals) came via the ED, and were frequently seen in 
that department.  When a bed became available, they were admitted to the 
acute surgical receiving unit.  If they were thought to be septic, they had care 
implemented as directed by the admitting team.  This usually consisted of 
intravenous fluids, antibiotics, blood cultures and possibly oxygen ± urinary 
output monitoring.  Lactate was rarely measured. 
There was definite scope to improve on the care being provided to patients with 
surgical sepsis and this coincided with the time that the Acute Physicians were 
keen to roll-out Sepsis Six to the surgical directorate. 
 Smartphone Technology 1.2
 Smartphone Evolution and Ownership Trends 1.2.1
Mobile telephones have progressively evolved in terms of computing power and 
the functionality available as processor speed, power consumption, memory 
costs and display technology have all improved.  The most significant telephonic 
innovation in recent time has been the smartphone.  A smartphone is defined as 
“a mobile phone that includes advanced functionality beyond making phone calls 
and sending text messages” (48).  Although the first device that could be 
regarded as a smartphone was released in 1994, functionality on early devices 
was limited.  Initially these devices simply integrated Personal Digital Assistant 
(PDA) technology, including email, into a mobile telephone.  Rapid evolution has 
resulted in today’s smartphone allowing the user to also take and display photos, 
play videos, surf the Web and use third-party applications (apps).  This ability to 
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run apps provides limitless functionality and is one of the main drivers for 
purchase. 
There are currently four main platforms in the smartphone market:  iPhone, 
Android, Blackberry and Windows.  Of these, Blackberry was first to market in 
1999 and enjoyed market dominance for many years, especially in the corporate 
sector.  In terms of global sales, it has been very much eclipsed by the other 
platforms in recent years.  One of the main reasons for this may be touch-screen 
technology, which was absent in most early smartphones.  The first iPhone 
(Apple Inc, Cupertino, CA, USA) was released in 2007 and was massively 
successful, selling 6.1 million units in the first year.  Most would regard this as 
the start of the smartphone revolution.  Third party app support came in 2008 
with Apple’s iOS version 2 and the launch of the Apple App Store.  This coincided 
with the release of the HTC Dream, the first smartphone using Android.  
Windows Phone, the consumer-targeted successor to the enterprise-orientated 
Windows Mobile, launched in 2010 with Windows Phone 7.  All platforms and 
handsets have been through many incarnations, with functionality substantially 
increasing as a result. 
Worldwide, in August 2012, Android was the most popular platform, generally 
having 60-65% market share to iPhone’s 20-35%; this was true for the USA, UK 
and China.  By May 2014, Android’s market share had risen further to 83% in 
China (at the expense of iOS and all minority players, such as Windows), stayed 
static in the USA and UK (but virtually all UK Blackberry users had transferred to 
iOS, increasing Apple’s market share)  (49).  Older platforms such as Symbian 
have almost no presence outwith developing economies. 
It is estimated that there are currently more than 1 billion smartphones and 
tablets globally, with this number rapidly rising year-on-year.  While the USA has 
been the market leader for many years, trends are changing and in 2012 the 
Chinese become the dominant smartphone market by volume, overtaking them 
(50).  Europe has previously also lagged behind but growth in smartphone 
ownership here too continues to flourish. 
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Smartphone ownership among doctors in Europe rose sharply between 2010 and 
2012.  In 2010 EPG Health Media (Europe) Ltd conducted a survey of 240 doctors 
in Europe and 100 doctors in the USA.  They then conducted a further survey on 
2012 to assess interval change.  While smartphone ownership has increased 
across both continents, it rose from 81 to 91% in the USA but from 44 to 81% in 
Europe; a significantly greater net increase in Europe. 
A 2011 survey of medical students and Foundation doctors in one English health 
region revealed that almost 75% of their respondents owned a smartphone, with 
68% of them owning an iPhone and 17% owning an Android-based smartphone 
(51).  This is supported by a survey of iPhone usage in anaesthetists in 2010 (52), 
a survey of doctors in the US in 2011 (53), and London junior doctors in 2011 
(54).  It is therefore obvious that for any medically targeted smartphone app to 
be successful it must be available for both Android and iPhone.  Given the 
relatively saturated smartphone market, this situation is unlikely to change 
significantly in the medium term. 
 3rd Party Applications 1.2.2
An “app” is a software application designed to run on mobile devices, such as 
smartphones and tablet computers.  They can be downloaded via App Stores, 
which are usually specific to the operating system of the mobile device, such as 
the Apple App Store, Google Play (Android), Windows Phone Store, and 
BlackBerry App World.  Consumers own varying numbers of apps but it is 
estimated that most have between twenty to thirty at any point in time, the 
most utilised of these being social media apps and games.  A well-recognised 
phrase of the last few years is “there’s an app for that” – recognising that 
smartphone and app technology have permeated every aspect of life in the 21st 
century. 
 Mobile Health Technology 1.2.3
The Global Observatory for eHealth (GOe) within the World Health Organization 
(WHO) defines mobile health (mHealth) as “medical and public health practice 
supported by mobile devices, such as mobile phones, patient monitoring devices, 
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personal digital assistants (PDAs), and other wireless devices”.  mHealth utilises 
all functions of mobile technology: from the use of commonplace features such 
as  voicemail and text messaging, to those functions involving wireless, 
Bluetooth and  global positioning systems (GPS) technology. 
Smartphone technology has galvanised the advances in mHealth.  The 3G and 
wireless capability of smartphones allows individuals to access information and 
advice from anywhere at any time.  They provide benefits over and above laptop 
computers – not just by way of their pocket-sized and thereby inherently 
portable nature – but also importantly utilising the GPS, sensor and camera 
functions – such as to provide the potential for teleconferencing or teleradiology 
at any point of the day or night. 
Over the past five years the smartphone has been recognised as having 
revolutionary potential for the practice of medicine  (55), (56), (57).  Not only 
could the smartphone replace a pager, mobile telephone, PDA, pocket textbook 
and diary – all while being lightweight and very portable – it had mobile internet 
that could allow the viewing of education videos via youtube.com and mobile 
viewing of podcasts. 
Much study has been undertaken into healthcare professionals’ acceptance of 
and uptake of smartphone technology in the workplace (58), (59). Chen and 
Putzer’s work in particular has shown that compatibility with existing technology 
in the workplace and knowing the device is secure and the functionality safe, 
were major predictors of adoption of smartphone technology.  Pre-existing 
comfort and familiarity with smartphone technology is another positive predictor 
and this is naturally associated with seniority: older doctors and/or those less 
comfortable with newer technologies may be disadvantaged by these rapid 
advances in mHealth (60). 
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 Healthcare Apps 1.2.4
Healthcare apps are now ubiquitous and come in myriad forms.  They have 
tended to be targeted at either the healthcare professional or the healthcare 
consumer (patient), with by far the larger number of apps targeted at patients.  
By mid-2013 there were more than 23,000 healthcare Apps available for 
download, with an estimated 1,000 new healthcare apps being released every 
month (61).  Of the currently available apps, over 7,000 were specifically 
designed for healthcare professionals; the remaining 16,000 were for patients.  
Those aimed at healthcare professionals had variable functionality, provenance 
and reliability and varied hugely in their aims – from simply being mobile 
guidelines, to performing calculations based on patient data, thereby providing 
clinical management advice.   
Medical reference apps such as Epocrates (free, regularly updated 
pharmacologic reference), Medscape (free regularly updated diagnostic and 
management reference texts) and DynaMed (full medical reference app from 
EBSCO Publishing) are very popular and respected apps, used by doctors across 
the US and UK.  These apps, however, while easily navigable, are not 
particularly interactive.  Apps do exist that allow inputting of patient variables 
in order to generate a patient-specific recommendation.  This smartphone-
specific interactivity makes smartphones distinct from their traditional cousins – 
hardcopy textbooks.  However, the obverse of this benefit is its risk: there is 
real potential for unintended outcomes.  This is why app development has 
become such a minefield.   
Apps have been evaluated for their potential benefit on performance and care 
provided, in a number of ways.  These range from performance of advanced life 
support using the iResus app (62), to guiding students through prescribing 
emergency drug infusions to a critically ill child (63), to teaching neonatal 
intubation (64).  Each of these studies concluded that smartphone technology 
conferred advantage over traditional teaching modalities, and should be 
explored further.  Conversely, use of an app for assessment and management of 
stroke (65) was found to be slower than traditional paper methods, and an app 
for the general public to aid cardiopulmonary resuscitation again proved a 
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slower modality, but interestingly more accurate (66).  An Australian group have 
suggested that these mixed findings may show that apps are more suitable for 
some tasks than others (67). 
One of the most pressing concerns with the unprecedentedly rapid worldwide 
embrace of healthcare apps has been lack of consistent quality within them and 
unclear authorship and provenance (68), (69), (70), (71).  Absence of declaration 
of medical professional involvement in content of apps has been noted and the 
need for doctors and other healthcare professionals have an important role to 
play in guiding app development has been widely expressed (72).  If patients and 
healthcare professionals alike start to become reliant on apps to aid provision of 
care, it is paramount to ensure that only apps of the highest quality, reliability 
and safety are marketed. 
 Regulation 1.2.5
App regulation remains a minefield as regulation is only required for those Apps 
that are classified as a medical device.  The US Food and Drug Administration 
(FDA) began drafting guidance on Apps several years ago, producing the first 
draft guidance in July 2011 (73). 
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) had been 
following suit and by January 2013 had approved its first App, Mersey Burns (a 
tool to calculate burn area percentages and fluid requirements)  (74). 
In March 2014 the MHRA released a position statement (75).  They compiled a 
list of words and phrases that they felt were associated with an App being a 
medical device :  
• amplify, analysis, interpret, alarms, calculates, controls, converts, 
detects, diagnose, measures, monitors 
There were certain on-going grey areas: “Software that provides general 
information but does not provide personalised advice, although it may be 
targeted to a particular user group, is unlikely to be considered a medical 
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device”.  However, “decision support or decision making software that applies 
some form of automated reasoning, such as a simple calculation, a decision 
support algorithm or a more complex series of calculations, e.g. dose 
calculations, symptom tracking, clinicians guides.  These are the types of 
software most likely to fall within the scope of the medical devices directives.” 
If it is determined that an App meets the definition of a medical device, it 
requires to be regulated by MHRA as such.  All medical devices need to be 
classified as they range from patient skin dressings (Class I, low risk) to 
implantable devices (Class III, high risk), and everything in between.  Following 
classification, conformity of the device needs to be assessed - where 
manufacturers demonstrate that their devices meet the essential requirements 
of the Medical Devices Directive, by Class. 
However, prior to 19/03/2014, and during the period of this research, the MHRA 
guidelines were simply for guidance, leaving it open to the developer’s 
interpretation on what an App did and the level of patient risk associated with it 
as to whether it should be classified as a device or not. 
The NHS itself is also attempting a degree of regulation and oversight over 
healthcare apps.  In March 2013 the NHS England’s Commissioning Board 
launched the Health Apps Library because they are “committed to improving 
outcomes for patients through the use of technology.”  All apps showcased on 
this website have been approved by a “clinical assurance team,” of doctors and 
nurses and must come from “trusted sources of information, such as NHS 
Choices,” (http://apps.nhs.uk/).   Currently these apps in the NHS Apps Library 
are for healthcare consumers rather than providers, but emphasise the 
important contribution that apps now make the healthcare and how much 
smartphone technology has been embraced in recent years.   
Overall, the feeling seems to be that app regulation is a positive move (76), but 
concerns from the US Congress that it may stifle mHealth innovation are 
acknowledged (77).  Assuming app regulation is conducted with clarity and 
transparency, it is likely only be beneficial to patient care, rather than a 
hindrance.   
Chapter 1  34 
It’s not only app regulation for quality assurance that is a potential minefield, 
data protection and patient confidentiality must be considered.  The Data 
Protection Act (1998)  (78) details the principles of “good information handling” 
as well as the rights of a patient to know how their personal data is handled and 
the responsibilities of the individuals and organisations who utilise and process 
this data.  The Information Commissioner’s Office (ICO) has issued the Bring Your 
Own Device (BYOD) document in an attempt to clarify the responsibilities of the 
data controller and individuals if an organisation permits and/or individual 
healthcare professionals utilise patient data on personal devices BYOD (79). 
 Existing Guideline Apps 1.2.6
Thromboprophylaxis 
Prior to the start of this research, there were two apps available on the Apple 
App Store relating to VTE prophylaxis.   
• Thrombosis Guidelines app (London, Guy’s and St Thomas’) 
o first released 14/7/11 
o This utilises the NICE guidelines for VTE treatment and prophylaxis 
(80) 
o Requires reference to several other pages within the main app to 
check for contraindications to AES and LMWH.  Minimally 
interactive. 
• Sanofi Clexane App 
o Pre-dated the start of this research in August 2012 
o Only available in French 
o No longer available via the Apple App Store 
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• SIGN 122 via SIGN app 
Sepsis Six 
At the time of starting this body of research, in August 2012, no Sepsis Six apps 
were available in the app stores for any platform.   
The first Sepsis Six app became available to download in December 2012.  This 
was marketed by the “Survive Sepsis” campaign and contained an interactive 
sepsis screening tool and an interactive “tick-sheet” for documenting completion 
of each element of the bundle.  It also guided the user through the escalating 
cascade of severity of sepsis, ensuring that organ function was evaluated.  Initial 
versions were not particularly user-friendly and updates during 2013 have 
improved on the original app. 
A further Sepsis Six app was launched in January 2013 but was non-interactive 
and had limited functionality.  Later that year the official NHS Scotland app was 
released in June 2013.  There was significant collaboration at a design level 
between this project and the team developing that app. 
Summary of available apps 
No suitable apps were available at the start of this research project; hence novel 
apps for both thromboprophylaxis and Sepsis Six were designed and evaluated. 
 Hypothesis 1.3
Compliance with simple guidelines is likely to be unaffected by the introduction 
of an app but that an app for more complex guidelines may show an 
improvement in compliance.   
Protocol-compliance fatigue is recognised as an issue, particularly in the closely-
regulated world of today.  Even if guideline compliance is improved with a novel 
modality, fatiguing of interest is likely with time 
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 Aims 1.4
To assess prevalence of smartphones in the doctor population in a three-site 
hospital board area and these doctors’ attitudes to smartphone technology for 
clinical uses. 
To design and implement novel apps for thromboprophylaxis and Sepsis Six as a 
supplemental modality for guideline dissemination. 
To assess the impact of the introduction of these apps on guideline compliance, 
including assessing for fatiguing of interest. 
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2 Materials and Methods 
 SurveyMonkey Questionnaire 2.1
 Description of Service 2.1.1
The survey was created using the SurveyMonkey online tool 
(https://www.surveymonkey.com).  SurveyMonkey is an extremely popular piece 
of online survey software.  It allows customisation of survey questions, a link to 
the questionnaire to be created and then the questionnaire to be distributed via 
a chosen mailing list, with collection of responses in real time.  Depending on 
requirements, a variety of options and packages are available, ranging from the 
free “Basic” package to the £779/year “Platinum” package. 
The SurveyMonkey “Select” package was purchased at £24/month for a total of 
four months.  This gave access to unlimited questions, up to 1000 responses per 
month, real-time results, skip-logic and downloadable and exportable results. 
 Identification of Recipients 2.1.2
It was decided that a suitably large subject population would be the cohort of 
doctors working in the Clyde sector of the Greater Glasgow & Clyde Health Board 
in August and September 2012.  This included all doctors of all grades and 
specialties employed in secondary care across Clyde. 
Email addresses for all doctors working across the three Clyde sites (Royal 
Alexandra Hospital, Paisley (RAH), Inverclyde Royal Hospital, Greenock (IRH) and 
Vale of Leven Hospital, Alexandria (VoL)) were obtained from the postgraduate 
administrators for RAH/VoL and IRH.  In addition all departments were 
approached via the secretaries to see if any doctors had recently been appointed 
who were not on the lists received from the postgraduate administrators.  This 
did indeed yield a further twenty doctors. 
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 Survey Details 2.1.3
Information requested in the SurveyMonkey questionnaire included 
demographics, Smartphone ownership, Smartphone usage, App ownership and 
usage and feelings towards specific locally applicable guideline-based Apps.  Full 
details of the questions posed and logic flow through the survey is listed in 
Appendix 1. 
Emails inviting participation in this survey were sent on 23/08/2012 to all 
Consultants, Associate Specialists, Specialty Doctors, Specialty and Core Trainees 
(ST and CT), General Practice (GP) trainees, Locum Appointment for Training 
(LAT) / Locum Appointment for Service (LAS) doctors and first and second year 
Foundation Year (FY1 and 2) doctors across all specialties.  The email included 
details of the research being undertaken, a brief resumé of the principal 
researcher and a link to the questionnaire on the SurveyMonkey website. 
The first few respondents were very helpful as this identified hitherto 
unpredicted responses to the survey questions.  Some smaller / niche specialties 
had not been included and there were glitches with the freetext boxes.  
Thankfully the survey link had been emailed out late at night and after a brief 
email correspondence with the first respondent, the survey was amended in 
real-time and all subsequent respondents able to access the fully satisfactory 
survey. 
Two weeks after the initial email, on 04/09/2012, a follow-up email invitation 
was sent to all identified doctors.  Three weeks following this, the survey was 
closed. 
 Ethics and Clinical Effectiveness 2.2
Ethical approval was applied for on 22/08/2012 to the Glasgow Research and 
Ethic Committee, via Dr Maureen Travers, Research Coordinator in the R&D 
Management Office at the Western Infirmary in Glasgow.  The REC response on 
02/11/2012 was that basically this was a comparison of audits, the development 
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and research aspect being in relation to the Apps and, as such, would not have 
to be dealt with by R&D. 
The Clinical Effectiveness department for Greater Glasgow and Clyde (GGC) 
were notified of the project as they require oversight of all projects conducted 
in GGC. 
 Intellectual Property 2.3
Intellectual property (IP) rights grant creators or owners of a work certain 
controls over its use.  The University of Glasgow does not automatically own 
intellectual property developed by a student, who will generally own the IP they 
develop during the course of their studies.   
On this basis, the IP of the Apps themselves remained with the author.  The 
actual guidelines used were widely available and reproduced in multiple formats 
already.  Consent was applied for from the relevant local committees for 
Thromboprophylaxis and Sepsis, to use the definitive local guidelines for the 
Apps and this was freely granted. 
 App Design 2.4
 Design Process 2.4.1
For both the DVT prophylaxis and Sepsis Six Apps an initial review was made of 
relevant apps currently available in each area for both the iPhone and Android 
platforms.  An assessment was made as to the suitability of any Apps identified 
for use in this project.  No apps identified met the specific requirements of this 
MSc project either in terms of functionality or user experience.  This was kept 
under review at three monthly intervals.   
Following review and consolidation of local and national guidelines in each area, 
a basic programme requirement was created to outline what the app should 
achieve and how this should be accomplished.  Detailed programme flow and 
logic was designed and tested on paper to ensure that the resulting app would 
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replicate the results of following existing forms of guideline delivery.  This was 
refined to exploit the advantages of a smartphone platform and provide 
additional benefit over simply reproducing a piece of paper. 
 Governance 2.4.2
Advice was sought from the lead pharmacist for surgery on the legalities and 
potential repercussions of incorrect prescribing resulting directly from using one 
of the apps developed for this thesis.  His concerns were as follows: 
• Robust governance needed as the guidelines subtly, but not infrequently, 
changed in the GGC Handbook. 
• The fact that a source of reference was being promoted other than those 
prescribed by hospital management was of concern.  While junior doctors 
were perfectly able to download (and use) any apps they liked from an 
app store, promotion as part of this work changed responsibility. 
• Responsibility for any errors would likely be shared between Author and 
User. 
• Consider directing the User to local guidance for extremes of weight, as 
this varied across health boards at the time of conducting the study. 
• Consider liaising with the Lead Haematologist and Thrombosis Committee 
in order to market the thromboprophylaxis app as endorsed by GGC. 
 Development Tools 2.4.3
Both iOS and Android applications were intentionally developed by Dr Andrew 
McCulloch as native apps with no reliance on internet access rather than as web 
based apps.  This was due to the lack of Wi-Fi available in the hospital and 
limited internet access generally due to “black spots”.  iOS apps were developed 
using the latest version of Xcode on an Apple Mac computer.  Android apps were 
developed using the Eclipse IDE with the Android SDK installed.   
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Although cross development tools exist that allow applications to be developed 
for both iOS and Android from a single codebase, there are limitations in this 
approach.  As the size of the apps was anticipated to be small, it was decided to 
develop native apps for both platforms.  Apps were initially developed for iOS 
with iterative refinements before a final version was ported to Android. 
iOS 
Xcode was used to develop the iOS application.  This is an Integrated 
Development Environment (IDE) provided free of charge by Apple and is 
exclusive to OS X, the operating system on Apple Mac computers.  A paid 
developer license is required in order to sign the application for deployment 
onto physical devices.  The Xcode IDE comes with a simulator that allows testing 
of apps on currently supported hardware.  Multiple versions of iOS can also be 
tested, provided these have already been installed on the development 
machine.  Typically only the most recent version of iOS is available for 
installation, however.  The Apple development documentation clearly indicates 
deprecated API calls and the earliest version of the operating system that 
supported functions are available on. 
In part due to Apple’s tight integration of software and hardware, there is rapid 
uptake of software updates.  The majority of users will be running the latest 
major version, if not the latest point release, within a short period of its 
release.  This greatly simplifies development of apps for iOS devices.  iOS 
version 6 was released on September 19th 2012.  Uptake of this in the last 11 
days of September is shown in Figure 2-1 and in Figure 2-2 it can be seen that 
60% of iPhones were running iOS6 in this period  (81). 
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Figure 2-1 - iOS 6 uptake after release 
 
 
Figure 2-2 - iOS version distribution for iPhone October 2012 
Android 
The Eclipse IDE is developed and provided free of charge by the Eclipse 
Foundation.  It is available for OS X, Windows and Linux operating systems and 
supports development for various languages and environments.  Specific plugins 
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for the Android platform are provided free of charge by Google.  This includes a 
simulator that can emulate the far more diverse range of devices running 
Android.  These can be configured with any standard version of Android released 
to date.  A number of device manufacturers, including Sony, customise the 
version of Android they deploy, which makes testing for all possible 
configurations more challenging.  Unlike Apple, no fee or license is required to 
deploy apps to physical devices.  A one time registration fee is required in order 
to distribute via the Google Play store. 
The range of OS versions in current use with Android is far greater than with iOS 
due to the variety of device manufacturers involved and their integration with 
mobile phone operators.  This is seen in Figure 2-3 which shows data from the 
Android developers’ site maintained by Google.  More than 50% of devices in 
November 2012 were running the Gingerbread version of the OS at API level 10, 
first released in February 2011.  Version 4.1, Jellybean, has achieved only 2.7% 
penetrance since being released in July 2012. 
 
Figure 2-3 - Android version distribution November 2012 
 Testing and Deployment 2.4.4
Given the timescales and potential regulatory hurdles involved, deployment of 
the apps to users was done manually, as a pilot, rather than via either the Apple 
App Store or Google Play.  This was achieved by loading the source code for both 
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versions of the app onto an Apple Mac with both Xcode and Eclipse installed and 
deploying directly onto users smartphones.  Testing was initially carried out by 
loading the app onto a single iPad and taking notes whilst supervisors and select 
colleagues used the app.  Once all were satisfied that the app was fit for 
purpose in terms of usability and its logic was robust and accurate, the app was 
ported from iOS to Android and then deployed onto subjects’ smartphones.  Any 
bugs or refinements required at this stage were fed back before the apps were 
updated and redeployed. 
 DVT App 2.4.5
First the DVT app asks the user to select the correct specialty before proceeding 
to highlight any risk factors for DVT in a scrolling list. 
 
This is then repeated for bleeding risks and any contraindications to anti-
embolism stockings. 
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Renal function and weight are then input before a final screen gives advice on 
the appropriate dose of low molecular weight heparin.  The ability to choose 
which low molecular weight heparin is used is provided. 
 
 
On pressing the “Restart” button on the Result screen, the user is taken back to 
the DVT Prophylaxis home screen.  This resets all values to the default ones as 
they are most commonly entered and minimises risk of using unusual and 
abnormal values left in from the last calculation.   
 Sepsis Six App 2.4.6
Following an initial start screen the user is asked to indicate what signs of 
systemic inflammation are present.  If 2 or more are present, a red and yellow 
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‘Sepsis’ sign begins to flash at the bottom of the screen.  Information pop-ups 
are provided to clarify the definition of altered mental state and that elevated 
glucose beyond 7.7mmol/L is primarily of relevance in non-diabetics. 
 
Assuming that the criteria for sepsis are met, the user is taken on to the Sepsis 
Six screen where all 6 elements are listed.  Clicking on one provides more detail 
and they can be scrolled through individually.  The antibiotic screen had been 
configured to provide the antimicrobial prescribing guidance for Greater 
Glasgow & Clyde.  The app has been programmed with an obsolescence date for 
these guidelines after which they will not be shown unless the app is updated.  
Should such an app enter routine use, subject to regulatory approval, these 
guidelines could be updated over the air.  It would also be possible to provide 
antibiotic guidance specific to their location.  This would require the co-
operation of multiple health boards and could use GPS location and geofencing 
to ensure the correct antibiotic guidelines are provided. 
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The next step in the app asks the user to assess for evidence of organ 
dysfunction.  Information pop-ups are used to provide definitions of the various 
parameters such as hypotension and acidosis while keeping the interface 
uncluttered.  If organ dysfunction is present the user now checks for septic 
shock. 
 
Should septic shock be present the user is provided with a summary of the 6 hour 
resuscitation bundle defined by the Surviving Sepsis Campaign.  The user is also 
encouraged to escalate the level of care the patient is receiving at this point.  
The end screen is a common exit point where the steps already taken are 
reiterated and the user is encouraged to regularly reassess the patient.  This 
helps to remind the user that Sepsis Six is the start of a treatment pathway, not 
a complete treatment in itself. 
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 Audit of Guideline Compliance 2.5
 Thromboprophylaxis 2.5.1
Baseline 
An initial audit of current practice was carried out over a two week period in 
December 2012 in both the acute surgical receiving ward and the main general 
surgical ward.  A snapshot of all patients in the receiving ward was conducted at 
the start of this cycle, as well as a snapshot of all patients in the general ward, 
ensuring any patients decanted from one to the other were omitted.  The 
following week a further snapshot of the receiving ward was conducted, this 
timescale having allowed virtually all patients from the previous week’s intake 
to have been discharged or moved on to other wards.   
The existing audit datasheet in use at RAH prior to this body of research was 
produced to collect the data required by SPSP for their on-going national audit : 
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Unfortunately this proforma provided little useful analysable information and a 
new one was designed to collect more useful data. 
The data collected about thromboprophylaxis prescribing and patient risk factors 
was as follows: 
• Ward, Date of admission, Elective vs. Emergency admission, Reason for 
admission 
• Demographics – Age, Gender, Weight (kg), Height (m) 
• Laboratory results – eGFR, Platelets  
• Medical/family history – Thrombophilia? Previous VTE personally, or in 
first degree family member? Current significant major medical condition? 
Hormone treatment? Cancer in last 2 years, or active cancer? 
• Bleeding risks – Active bleeding? Already anticoagulated?  
• Contraindications to AES – PVD, Leg neuropathy, leg/foot ulcers, “tissue 
paper skin” of legs, major limb deformity, cellulitis/massive oedema 
• Details regarding prescribing – Was LMWH prescribed? Type? Dose? What 
was the correct dose? Was this the dose prescribed? Were AES prescribed? 
Were AES being worn? Should AES have been prescribed? 
• Did the researcher need to change a prescription for safety? If so, how? 
All data was collected as discretely as possible to try and maintain a single-
blinded study.  The purpose of this was to minimise contamination of the data at 
each audit cycle, in order to be able to attribute change to a specific 
intervention. 
The elements of the dataset were collected from a variety of sources: the 
electronic Patient Management System (TrakCare) provided details of exact date 
and time of the patient departing the Emergency Department (ED).  This was 
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used as a surrogate for arrival in the receiving ward as the time recorded in the 
medical and nursing notes for admission was on first contact with the patient 
during clerking-in.  This provided an erroneously tardy time if the ward was 
busy.  The nursing clerk-in and notes provided details of the type of admission, 
some details relating to the reason for admission (although this was sometimes a 
little simplistic), demographics and vital statistics for the patient, as well as 
documentation on skin quality and contraindications for AES.  The medical notes 
were scrutinised for precise diagnosis/reason for this admission and past medical 
history, including that of cancer, PVD or bleeding risks/pre-existing 
anticoagulation.  The electronic laboratory system was interrogated for results 
for platelet count and estimated Glomerular Filtration Rate (eGFR) The drug 
chart provided further information on pre-existing anticoagulation, hormone 
therapy and the details of what, if any, LMWH and/or AES were prescribed, and 
when. 
Deployment of Thromboprophylaxis App 
The concept of a thromboprophylaxis app using GGC guidelines was discussed 
with the lead for thromboprophylaxis at RAH, Dr Chris Foster (Consultant Acute 
Physician, Royal Alexandra Hospital) and, through him, the GGC Thrombosis 
committee.  With Dr Foster having seen and used the app and happy with its 
logic and safety, and with the direct backing of the app by the surgical 
consultants at RAH, they gave their blessing to proceed with the app. 
The thromboprophylaxis app was designed concurrently with the audit and 
revised and refined over the first few months of 2013.  The app was deployed 
manually, over the space of a week, onto the smartphones of all doctors in the 
surgical department at RAH who were keen to try it.  Simultaneously a poster 
promoting the existence of the thromboprophylaxis app was displayed in all 
clinical areas and junior doctors’ offices (Appendix 9).  To capitalise on 
enthusiasm that surrounded the novelty of having an app for standard 
prescribing tasks, the next audit cycle was started just ten days after the app 
was deployed to the last volunteer, at the end of April 2013. 
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A final audit cycle was undertaken three months later, in September 2013, to 
assess for “app fatigue”.  Again, this utilised the same dataset as before and was 
single-blinded.   
 Sepsis Six 2.5.2
The introduction of Sepsis Six to the surgical directorate was fully supported 
and, indeed, strongly encouraged by the Acute Physicians, Clinical Nurse 
Manager for Surgery and the Service Manager for General Surgery.  Endorsement 
was given to proceed with this app project, in order to try to achieve the SPSP 
targets for sepsis that were currently unrecorded and, quite probably, unmet. 
Time Zero 
Given the absence of any data relating to the incidence and prevalence of sepsis 
in the acute surgical receiving unit at RAH, the initial phase of this research 
project was to audit this unknown area.  This was an invaluable opportunity to 
conduct a true Time Zero review of the scope of the problem.  It was felt that a 
two week period collecting data on all consecutive patients admitted to the 
acute receiving unit would provide a manageable, yet representative sample.  
Capturing all patients was the first challenge – to ensure veracious 
determination of prevalence of sepsis, an accurate denominator was required.  
From 08:00 Monday of the two-week cycle until 08:00 Monday, a fortnight later, 
all patients admitted through the surgical receiving ward, no matter how briefly, 
were included.  To ensure no-one was missed, daily meticulous review of 
TrakCare for all patients who were recorded as admissions to the receiving ward 
was undertaken.  Recording of the discharge destination for all patients who 
came through the ED was mandatory and all patients, even GP referrals, came 
through the ED.  Once the name and unique patient identification number (CHI 
number) was known, the patient and their case notes were tracked down to 
their current ward for review. 
The data required was collected from similar sources as utilised for the 
thromboprophylaxis arm of this research.  For this Sepsis Six arm, it was 
paramount that date and time were recorded and, again, the most accurate 
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method of doing this was to use the surrogate of departure time from the ED (a 
corridor journey of fewer than five minutes).  The medical notes were 
scrutinised for diagnosis and entries about possible Sepsis Six interventions, and 
the dates of any surgical procedures that might influence physiology, or indeed 
have been undertaken to achieve source control of infection; the NEWS charts in 
the patients’ notes at the end of each bed provided information on physiological 
parameters at each point of recording, as well as the calculated NEWS score 
documented.  The nursing notes provided dates (and times) of discharge as well 
as whether they had recognised a NEWS >4 and had taken appropriate action – 
such as triggering Sepsis Six, delivering the bundle elements they could, and 
informing the FY1 to urgently review the patient. 
Time Limits for Completion of Each Element of Sepsis Six Bundle 
Limits were set for completion of each Sepsis Six element where it had been 
instigated pre-trigger.  Clearly the post-trigger limit was 60 minutes.  After 
evaluation of the practicalities and weighting of each element, the following 
limits were set for analysis: 
IV fluids – any time pre-trigger 
Oxygen – any time pre-trigger 
Blood cultures – up to 24 hours pre-trigger 
Antibiotics – up to 12 hours pre-trigger 
Lactate – up to 6 hours pre-trigger 
Full blood count – up to 6 hours pre-trigger  
Urinary catheter – any time pre-trigger 
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Introduction of Sepsis Six 
Following the Time Zero audit, the concept of Sepsis Six was introduced and 
disseminated to all surgical doctors at the monthly departmental meeting on 
07/11/2012.  This involved a presentation detailing the prevalence of sepsis in 
the acute surgical patients – as evaluated from the Time Zero audit – and a 
succinct re-cap on the physiological changes that take place in a septic patient; 
this set the scene for why each element of the Sepsis Six bundle has its place in 
emergency resuscitation, and the relative impact on mortality per hour of delay 
for failure to implement each particular step.  The existing RAH Sepsis Screening 
posters (from the Acute Physicians) and stickers (Appendix 10) were examined to 
ensure familiarity and understanding in how to use them.  The critical 
importance of going that step further, once Sepsis Six had been delivered, of 
assessing the patient for organ dysfunction was also emphasised.   
It was recognised by that buy-in and support from the nurses in the receiving 
ward was integral (to the point of paramount importance) to the adoption and 
integration of Sepsis Six into the ward environment.  Between January and March 
2013 small group sessions were held in Sister’s office in the acute receiving 
ward, ensuring that virtually all nurses currently working in the ward could 
attend a session.  A similar presentation (to that the doctors received) was 
given, tailored to them, about the importance, consequences and potential 
interventions of unchecked sepsis.  These sessions were warmly received and the 
nurses very enthusiastic about a slight role-extension to permit delivery of some 
elements in an agreed protocolised fashion.  It was agreed that, on identification 
of NEWS >4 the initiation of the oxygen and IV fluid components of Sepsis Six 
would be nurse-led.  These are components that are relevant to anyone with 
deranged physiology, whatever the underlying cause.  At the same time the ward 
Foundation Doctor would be paged to attend, assess the patient for presumed 
sepsis, and instigate the remaining parts of the bundle.  The ward nurse would 
also place a Sepsis Six sticker in the medical notes, dated and timed at the point 
of sepsis recognition, and initial beside the elements they’d completed. 
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Sepsis Six Adjuncts 
One of the key strategies that seemed to facilitate timely completion of the 
Sepsis Six bundle in MAU was the presence of the Sepsis Six trolley.  This was a 
portable stand-alone unit with clearly labelled drawers, each containing supplies 
of equipment necessary to deliver each specific element of Sepsis Six (with the 
exception of intravenous antibiotics).  It was clear that this would be of great 
importance in aiding implementation in the surgical receiving ward too.  A 
thorough examination of the trolley and its contents was undertaken and 
potential areas the surgical trolley could reside in the receiving ward assessed.  
After in-depth consultation with the Ward Charge Nurse and evaluation of a 
number of potential units, it was decided that the best site would be next to the 
Resuscitation Trolley.  The surgical Sepsis Six trolley was stocked with all 
necessary supplies and sundries, laid out in a logical sequence.  All drawers and 
their contents clearly labelled and a laminated stock-check sheet compiled to 
aide restocking (Appendix 8).  It was agreed that ensuring the trolley remained 
optimally stocked at all times was the responsibility of the ward nurses, just the 
same as the Resuscitation Trolley 
Given that this was just the beginning of Sepsis Six in surgery, a conscious 
decision was made to utilise other existing resources that had worked well in 
medicine, namely the stickers to document completion of each element, and the 
posters (Appendix 10).   
First Audit after Sepsis Six Introduction 
Shortly following this introduction and briefing to all involved parties, the next 
audit cycle was conducted at the end of January 2013, again over a two week 
period and examining all consecutive patients admitted as emergencies.  
Precisely the same methods of data retrieval and parameters were used.  A 
further two months later, compliance was re-audited in March 2013 to assess for 
potential fatigue, with identical methodology as the two preceding cycles. 
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Sepsis Six App 
In May 2013 the Sepsis Six app was manually deployed, over the space of a week, 
onto the smartphones of all doctors in the surgical department at RAH who were 
keen to try it.  Tutorials and guidance through all the functions of the app were 
provided.  A short period of time was allowed to elapse following app 
deployment and then post-app audit was conducted at the end of June 2013, 
with a follow-up cycle in late July 2013 to assess for fatigue.  Again, identical 
methods were used as in the previous cycles. 
Back-to-Basics 
In July an interim analysis of the results to date indicated that the Sepsis Six app 
wasn’t improving guideline compliance to any significant degree.  Despite all the 
strategies of information dissemination (including the novel smartphone app) so 
far, there was clearly more to do to raise its profile.  A back-to-basics approach 
was decided upon, using high-visibility posters.  The hope was that this would be 
visually prominent in all clinical areas and keep sepsis at the forefront of 
everyone’s consciousness and daily priorities.  The posters were designed and 
printed specifically for this research project, and were put up in every clinical 
area of the RAH surgical department during the first week of August. 
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Using identical audit methodology as all previous cycles, the first audit after the 
poster intervention took place in September 2013 and the final audit cycle for 
the whole Sepsis Six project in December 2013, as before, to assess for fatiguing 
of interest.   
 End of project focus group 2.5.3
During the last week of the academic year, just prior to the August changeover 
of all junior doctors, a focus group was held with six FY1 doctors to find out 
their thoughts and opinions on the two arms of the smartphone project.  This 
consisted of a short anonymous paper questionnaire, with tick boxes for each of 
four areas.  They could tick as many or as few responses as they felt applied to 
them.  The information provided here fuelled the back-to-basics approach 
detailed above. 
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3 Results 
 Smartphone Survey 3.1
 Response Rates 3.1.1
A total of 456 doctors were surveyed and a total of 201 (44.1%) responded – a 
pleasingly high response-rate for doctors.  126 of the final 201 who responded 
did so within 4 days of the survey being sent out.  Responses had plateaued by 
day 10 (Figure 3-1).  A second email on day 14 to prompt completion of the 
survey resulted in a further prompt response – 40 surveys completed within 72 
hours. 
 
Figure 3-1 – Cumulative responses to survey 
258/456(56.6%) of those invited were male and 198 (43.4%) female.  Of those 
who responded to the survey, 123/201 (61.2%) were male and 76 (37.8%) female; 
2 (1.0%) declined to answer.  Proportionately more men (123/258, 47.7%) 
elected to respond to the survey than women (76/198, 38.4%), based on the 
gender of those invited to participate. 
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Proportionately more consultants and specialty doctors (107/217, 49.3%) elected 
to respond to the survey than those in junior grades – based on the grade of 
those invited to participate (Table 3-1, Figure 3-2) 
 FY1 FY2 CT/ST Cons/SAS 
Proportion of 
invited doctors 
who responded 
per grade (%) 
19/54  
(35.2%) 
16/47  
(34.0%) 
59/138  
(42.8%) 
107/217 
(49.3%) 
Table 3-1 – Responses by grade 
 
Figure 3-2 – Responses by grade 
Those responding to the survey were more likely to be under than over 40 years 
of age (121 under 40 versus 80 over 40 - Table 3-2). 
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Age Number of doctors who replied by age (%) 
(n=201) 
20-29 61 (30.3%) 
30-39 60 (30.0%) 
40-49 42 (21.4%) 
50-59 30 (14.9%) 
60+ 5 (2.5%) 
Declined to disclose 2 (1.0%) 
Table 3-2 – Age of respondents 
Both of the doctors who declined to disclose their age were Consultants. 
 Smartphone Ownership 3.1.2
180/201 (89.6%) owned a smartphone; 21/201 (10.4%) did not. There was no 
significant difference in ownership between males and females (p = 0.71, 
independent sample T-test).  There was near universal ownership of a 
smartphone within training grade doctors, particularly at Core Trainee level and 
below.  Other than GP trainees and specialty doctors who were under-
represented in the survey, the lowest percentage smartphone ownership was at 
consultant grade.  However, there was no statistically significant between the 
grades (p=0.27 Chi-Square). 
 
 Do you own a smartphone? Total 
Yes No % Yes 
Consultant 86 14 86% 100 
ST3+ 31 3 91% 34 
Core Trainee 21 0 100% 21 
FY1 19 0 100% 19 
FY2 15 1 93.8% 16 
GPST 3 1 75% 4 
Specialty Doctor 5 2 71% 7 
Total 180 21  201 
Table 3-3 – Ownership of smartphones by grade 
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Figure 3-3 – Ownership of smartphones by grade 
 
A clearer pattern of ownership emerges if we look at smartphone ownership by 
age (Figure 3-4).  All respondents under the age of 30 owned a smartphone.  
There was a clear trend to decreasing smartphone ownership with increasing age 
that was statistically significant (p < 0.001, one-way ANOVA).  This explains the 
trend seen with clinical grade as this correlates with increasing age. 
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Figure 3-4 – Ownership of smartphones by age 
 
Levels of smartphone ownership were similar across all specialties (Table 
3-4)with the exception of Obstetrics & Gynaecology where only 8 of 11 doctors 
(72.7%) owned a smartphone. 
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Specialty Number of doctors who owned a smartphone by specialty (%) (n=201) 
General medicine & medical specialties 53/58 (91.4%) 
General surgery 26/29 (89.7%) 
Orthopaedics 15/16 (93.8%) 
Surgical subspecialties  
(ENT / urology/ ophthalmology etc) 
8/9 (88.9%) 
Anaesthetics / ITU 26/28 (92.9%) 
Emergency medicine 16/16 (100%) 
Obstetrics & Gynaecology 8/11 (72.7%) 
Paediatrics 4/5 (80.0%) 
Radiology 6/7 (85.7%) 
Pathology / Laboratory medicine 4/6 (66.7%) 
General Practice 7/8 (87.5%) 
Psychiatry 7/8 (87.5%) 
Table 3-4 – Ownership of smartphones by specialty 
Of these 21 doctors who did not own a smartphone at the time of the survey, 
17/21 (81.0%) would consider owning one in the future. The remaining 4/21 
(19.0%) would not. Of these 4, 3 were male and 3 were Consultants, the other 
being an SAS. All were aged 40 or older. 
The majority of respondents to the survey who owned a smartphone owned an 
iPhone (Table 3-5).  A significant minority (21.7%) owned an Android-based 
smartphone.  It is, therefore, clear that whilst an iOS-targeted app will reach 
over 70% of medics, Android support is essential.  There is significant, usually 
tongue-in-cheek, rivalry between platforms that came through in some of the 
responses – Apple owners are referred to as iSheep or Fanboy, the corresponding 
“insult” being Fandroid.  The once dominant market position of Blackberry is a 
thing of the past in general and our survey group had negligible ownership.  It 
should be noted that the survey was conducted before the Windows Phone 7 
gained any significant market share, hence the minimal numbers seen in the 
survey. 
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Smartphone Platform No of doctors owning this phone (n=180) 
iOS (iPhone) 131 (65.2%) 
Android (Samsung, HTC, Sony) 36 (17.9%) 
Blackberry 9 (4.5%) 
Windows Phone 7 4 (2.0%) 
Table 3-5 – Type of smartphone owned 
 Smartphone Usage and Ownership of Medical Apps 3.1.3
110/178 (61.8%) of doctors reported using their smartphone for patient care. 
However, of the 68 doctors who did not consider that they used their 
smartphone for patient care, 28 (41.2%) owned medical-related Apps and, of 
these 28 doctors, 9 (32.1%) used these Apps regularly – suggesting that they were 
in fact unconsciously using their smartphone for patient care. These doctors 
were distributed across the more senior grades (4 Cons/SAS doctors and 5 ST/CT 
doctors).  Recoding these doctors gives a revised total of 119 (66.6%) doctors 
using their smartphone for patient care. 
It was noticeably core and specialty trainees (44/55 (80.0%)) who were leading 
the way in using smartphones for patient care. There was a steady increase 
through the Foundation years in use of smartphones for this purpose – then a 
tailing off at consultant grade.  This should not be taken to mean that 
consultants lose the ability to use smartphones.  This is a single snapshot in time 
which highlights that the young are more eager adopters of new technology.  
The consultant grade spans three decades – from mid 30s to age 65 and beyond.  
We have already seen that smartphone ownership currently falls with age (Figure 
3-4).  Were this survey to be repeated in 10 years, we would likely see an 
increase in smartphone ownership among consultants as today’s juniors’ progress 
in their careers. 
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 FY1 FY2 CT/ST Cons/SAS 
Proportion of 
doctors who used a 
smartphone for pt 
care, by grade 
6/18 
(33.3%) 8/15 (53.3%) 44/55 (80.0%) 61/90 (67.8%) 
Table 3-6 – Use of smartphones for patient care by grade 
Type of usage of smartphone No of doctors using this function 
Generic smartphone functionality 
(Admin – phone/text, email, diary, notepad; Camera; Torch; 
Map function; Calculator; Internet) 
76 
Medical Apps 92 
Logbook 9 
Audit/data collection 4 
Table 3-7 – Patterns of smartphone app usage 
Many doctors also reported that they used their smartphone to look up drug 
information or perform dose-calculations – either using an App or online 
tools/resources. 
 Receptiveness to Official Apps 3.1.4
164 of the 180 who responded to this question would be interested in apps 
specifically designed for patient care that used local or national guidelines.  
There was a strong expectation that apps developed by the local trust, or by 
national bodies, should be available free of charge.  This is a reasonable position 
to take, particularly for permanent members of staff who are unlikely to change 
trusts with any degree of frequency.  It would be more difficult to find 
agreement if apps and their development costs were trust-specific rather than 
via a national body such as NES. 
23% of respondents would be comfortable paying £1.99 for an app (Table 3-8).  
Up to £5 would be acceptable for 4 respondents and 2 would pay up to £10. 
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 Number Percent 
 
Did not say 19 10.6% 
£0.49 12 6.7% 
£0.99 29 16.1% 
£1.99 42 23.3% 
Free 50 27.8% 
Other (please specify) 28 15.6% 
Table 3-8 – Price willing to pay for official apps 
Significant interest was generated from several consultants in other specialties.  
This lead to collaboration with one of the obstetric trainees and his consultant 
and the addition of post-delivery DVT prophylaxis pathway to the DVT app being 
developed for this project.  That was, however, not specifically tested within 
this project – this research was confined to general surgical inpatients. 
There was also interest from one of the Emergency Department consultants who 
has involvement with an app used by the Emergency Medical Retrieval Service 
(EMRS).  With the EMRS app patient data is securely stored on a remote server 
and transferred to mobile devices as required.  This is an approach used by many 
apps, particularly when data must be synchronised across a number of devices.  
However, it the resources it requires included a server and the funding to 
maintain it, something only available to large bodies such as trusts or national 
bodies. 
 Concerns 3.1.5
126 of the 180 respondents who owned smartphones did not have any concerns 
about their usage in a clinical setting (Figure 3-5).  The most commonly cited 
concern (32/180) was of the accuracy and reliability of apps.  This included 
some concerns about how apps were to be kept up to date.  This would suggest 
that apps developed or endorsed by regional or national would find more favour 
than those from small independent developers – the enthusiastic amateur.  
Confidentiality and appearing unprofessional were infrequently cited concerns 
(7/180 and 4/180 respectively).  One comment was made that whilst there 
might be perceptions of being unprofessional at present, the increasing role of 
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technology in medicine means this will be seen as the norm and no different to a 
General Practitioner consulting a paper copy of the British National Formulary. 
A further comment made by one survey respondent raised concerns over patchy 
mobile internet availability within hospitals.  Mobile phone reception, 
particularly fast (3G/4G) data connections can be problematic within buildings.  
The prospect of allowing a large number of frequently changing devices access 
to a secure hospital Wi-Fi network is something that is likely to be unpalatable 
to local IT departments.  This would be of importance where data needed to be 
pulled from, or pushed, to a remote server in order to allow the app to function. 
 
Figure 3-5 – Concerns about clinical smartphone use 
 
 Thromboprophylaxis 3.2
The primary audit cycle was conducted in December 2012 pre-App. The 
thromboprophylaxis App was deployed in April 2013 and a post-App audit was 
Chapter 3  67 
conducted in May 2013. A follow-up cycle was completed in September 2013 to 
assess for potential fatigue of interest. 
 Baseline Audit 3.2.1
116 patients were identified during this period, 101 of whom were emergency 
admissions.  AES were indicated in 91 patients (91.4%)but were only applied 
correctly (indicated, prescribed and patient wearing them) in 34 (29.3%).  AES 
not being prescribed where indicated, or not applied even when prescribed, 
were both common at 31% and 31.9% of the sample respectively (Table 3-9). 
 
 Number Percent 
 
No error 34 29.3 
Indicated, not prescribed 36 31.0 
Prescribed, not applied 37 31.9 
Not indicated but prescribed 4 3.4 
On appropriately but not prescribed 5 4.3 
Total 116 100.0 
Table 3-9 – Accuracy of AES prescription (baseline) 
The prescription of Low Molecular Weight Heparin did somewhat better.  It was 
indicated in 104 of the 116 patients and prescribed correctly (or omitted if not 
indicated) in 100 patients.  Of the remaining 16 patients, 10 had no LMWH 
prescribed where it was indicated and 6 had the wrong dose prescribed (Table 
3-10). 
 
 Number Percent 
 
No error 100 86.2 
Indicated, not prescribed 10 8.6 
Wrong dose 6 5.2 
Total 116 100.0 
Table 3-10 – Accuracy of LMWH prescription (baseline) 
 App Introduction (early) 3.2.2
84 patients were identified in this period, 76 being emergency admissions.  AES 
were indicated in 76 patients (90.5%).  They were applied correctly in 38 
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(45.2%).  Failure to prescribe where indicated was common at 21/84 (25%) as 
was AES not being worn when prescribed (Table 3-11). 
 
 Number Percent 
 
No error 40 47.6 
Indicated, not prescribed 21 25.0 
Prescribed, not applied 18 21.4 
Not indicated but prescribed 2 2.4 
On appropriately but not prescribed 3 3.6 
Total 84 100.0 
Table 3-11 – Accuracy of AES prescription (app early) 
The prescription of LMWH was done well (Table 3-12).  It was prescribed 
correctly in 70/84 patients (83.3%).  It was not prescribed where indicated in 9 
(10.7) and prescribed where not indicated in 2 patients (2.4%).  The dose was 
incorrect in 3 patients. 
 
 Number Percent 
 
No error 70 83.3 
Indicated, not prescribed 9 10.7 
Wrong dose 3 3.6 
Not indicated but prescribed 2 2.4 
Total 84 100.0 
Table 3-12 – Accuracy of LMWH prescription (app early) 
 App Introduction (late) 3.2.3
Due to a change in ward staff during this final audit period, a small number of 
data points were missing.  There were a total of 79 patients in this period, all of 
whom were emergency admissions.  AES were only applied correctly in 23 
patients (29.1%).  AES were not prescribed where appropriate in 25 (32.9%) 
patients, and not applied where prescribed in 22 (27.8%) of patients (Table 
3-13). 
  
Chapter 3  69 
 Number Percent 
 
No error 23 29.1 
Indicated, not prescribed 26 32.9 
Prescribed, not applied 22 27.8 
Not indicated but prescribed 1 1.3 
Total 72 91.1 
    
Missing 7 8.9 
Table 3-13 – Accuracy of AES prescription (app late) 
LMWH was prescribed correctly in 58(73.4%) of patients in this period.  It was 
not prescribed where indicated in 8 (10.1%) and had an incorrect dose prescribed 
in 2 patients (2.5%) (Table 3-14). 
 Number Percent 
 
No error 58 73.4 
Indicated, not prescribed 8 10.1 
Wrong dose 2 2.5 
Total 68 86.1 
    
Missing 11 13.9 
Table 3-14 – Accuracy of LMWH prescription (app late) 
 Trends 3.2.4
Anti Embolism Stockings 
With the introduction of the thromboprophylaxis app there was a significant 
increase in the proportion of AES prescribed and applied correctly as a binary 
result (29.3 vs. 47.6%), p = 0.02, Independent samples T-test.  This improvement 
lost significance when baseline pre-app data was compared to the 2nd audit 
period post introduction (app-fatigue) (Figure 3-6).  Missing data and a change in 
junior staff may be partly to blame in addition to a genuine app fatigue effect.  
The second audit period took place in April and June when the junior doctors 
most likely to be prescribing AES (FY1s) are fairly experienced and au fait with 
local protocols.  In contrast, the third period assessed doctors 6-8 weeks into 
their job.  This is a period when most will have settled in but still be relatively 
inexperienced. 
Chapter 3  70 
 
Figure 3-6 – Proportions of patients with correctly applied AES (binary result) 
Much of the missing data was documentation as to whether the AES were 
actually being worn.  However, the proportion of patients in whom AES were 
indicated but not prescribed had risen to pre-app levels.  Overall the type of 
error made in AES prescription remained similar across all three audit periods 
(Figure 3-7). 
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Figure 3-7 – AES prescribing accuracy across 3 audit periods 
Low Molecular Weight Heparin 
In contrast to AES, LMWH was prescribed very well, even at baseline.  There was 
actually a small decrease in the percentage of LMWH prescribed correctly in the 
first pre-app audit period.  This is shown in Figure 3-8 where the result is given 
as a binary yes/no as a percentage of all patients in that group. 
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Figure 3-8 – Correct prescription of LMWH across 3 periods as binary result 
Over the three audit periods there was little variation in the proportions of the 
type of error being made in LMWH prescriptions (Table 3-15, Figure 3-9).  These 
differences were not significant (p=0.48, Chi-Square). 
 
 Audit period 
Pre-App 
App 
Introduced 
App Fatigue 
 
None 
N 100 70 58 
% 86.2% 83.3% 85.3% 
Indicated, not prescribed 
N 10 9 8 
% 8.6% 10.7% 11.8% 
Wrong dose 
N 6 3 2 
% 5.2% 3.6% 2.9% 
Not indicated but prescribed 
N 0 2 0 
% 0.0% 2.4% 0.0% 
Total N 116 84 68 
Table 3-15 – LMWH prescribing accuracy across 3 audit periods 
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Figure 3-9 – LMWH prescribing accuracy across 3 audit periods 
Even with selection of the correct dose where one might expect improvement 
from an app that prompts for body weight and renal function, there was no 
significant improvement in dosing between any of the audit periods (p=0.38, 
one-way ANOVA).  The performance in correctly reducing the LMWH dose is 
shown in Table 3-16. 
This suggests that complacency in the prescription of LMWH is playing a hand.  
As LMWH is generally prescribed well without a smartphone app, prescribers may 
feel there is no need to consult such an app.  This is perhaps true of LMWH 
prescription in medicine and surgery where dosing is simple, but may be less 
applicable in more complex situations such as obstetrics where dosing is more 
weight and intervention based.   
 Dose 
Correct Wrong 
Audit Period 
Pre-App 14 2 
App 14 1 
App Fatigue 5 2 
Total 33 5 
Table 3-16 – Number of patients with incorrect LMWH dose where reduced dose required 
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There were only 11 incorrect LMWH doses in total prescribed across the three 
periods (Table 3-17).  The most common error was failure to reduce the dose of 
LMWH to take account of low body weight or renal impairment.  This occurred in 
5 of 38 cases (13.2%) where there should have been a dose reduction. The dose 
was unnecessarily reduced in 6 of 241 cases (2.5%).  This may be due to several 
factors:  previous guidelines in surgery have suggested a standard dose of 20mg 
enoxaparin (this has been revised to 40mg); uncertainty of renal function and 
the threshold for dose reduction (especially in borderline cases); and initial 
inaccurate assessment of patient weight (guesstimate). 
 
 Dose 
Correct Wrong 
Reduced dose 
LMWH required 
No 
Count 235 6 
% within Reduced dose 
LMWH required 
97.5% 2.5% 
Yes 
Count 33 5 
% within Reduced dose 
LMWH required 
86.8% 13.2% 
Total 
Count 268 11 
% within Reduced 
dose LMWH required 96.1% 3.9% 
Table 3-17 – Accuracy of LMWH dosing regardless of what dose was indicated 
 
 Sepsis 3.3
 Baseline Audit 3.3.1
Prior to this initial audit cycle no data existed as to the prevalence of sepsis in 
acute surgical patients at this institution. A primary aim was to evaluate this, as 
well as the actual numbers of patients being admitted weekly. 
There were 181 admissions over a 2 week period (178 unique patients). 
• 56 admissions with presumed or confirmed infection (31%) 
• 22 admissions with pure inflammation (e.g. pancreatitis) (12%) 
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• 14 admissions with problems associated with advanced malignancy (8%) 
• 89 “other” admissions (e.g. pain, colic, trauma) (49%) 
 
15 of the 181 admissions scored ≥5 on NEWS chart while in the acute receiving 
ward (8.3%) where the elevated NEWS score was thought secondary to infection. 
Of these only 13 (86.7%) had an SIRS score of ≥2 i.e. fully met the definition of 
sepsis.  The remaining 2 patients had a SIRS score of 1 each.  One patient had a 
diagnosis of urinary sepsis, the other cholecystitis.  Both had significantly 
elevated white cell counts. 
Mean and median times for completion of each element are in Table 3-18.  
These include all cases where an element was done, not just those within the 
Sepsis Six time limits.  Negative values indicate that an element was already 
completed prior to Sepsis Six being triggered by an elevated NEWS score.  
Percentage completion rates are for elements completed within the Sepsis Six 
constraints only. 
 Median (mins) Mean (mins) % Completion 
Oxygen -45 -592.5 73.3% 
IV Fluids -180 -874.2 66.7% 
Blood Cultures -55 -238.8 26.7% 
IV Antibiotics -480 -749.3 66.7% 
Lactate -20 -6.7 13.3% 
Full Blood Count -60 -194.9 33.3% 
Accurate Urine Output -120 -885.6 40.0% 
Table 3-18 – Element completion (baseline) 
Boxplots for the time to complete each element are shown in Figure 3-10. 
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Figure 3-10 – Boxplot of time to element completion (baseline) 
No patient had a complete Sepsis Six bundle delivered.  The process was only 
formally documented in 1 patient which is, in part, explained by the fact that 
Sepsis Six had not been formally rolled out at this stage.  Mean NEWS score at 
time of trigger was 6.6 and mean SSI score 2.5. 
 
 Sepsis Six Introduction (early) 3.3.2
A total of 13 of 181 patients activated the Sepsis Six protocol with an elevated 
NEWS score due to infection.  The mean NEWS score for those that triggered was 
5.6, and mean SSI score was 1.85.  Only 2 of the 13 patients had the Sepsis Six 
process formally documented in casenotes.  No patient had organ dysfunction 
formally assessed.  No patient had a complete Sepsis Six package of care 
delivered. 
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 Median (mins) Mean (mins) % Completion 
Oxygen -200 -226.1 100% 
IV Fluids -545 -839.5 76.9% 
Blood Cultures 17.5 -96.9 53.8% 
IV Antibiotics -485 -775.5 38.5% 
Lactate 57.5 68.8 15.4% 
Full Blood Count -76 -21.6 38.5% 
Accurate Urine Output -395 -372.5 15.4% 
Table 3-19 – Element completion (Sepsis6 early) 
 
Figure 3-11 – Boxplot of time to element completion (Sepsis6 early) 
 Sepsis Six Introduction (late) 3.3.3
12 of 141 patients triggered Sepsis Six during this period.  One patient with post 
endoscopic ultrasound pancreatitis triggered twice (2 consecutive days) and 
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there were, therefore, 11 unique patients.  Mean NEWS score at time of trigger 
was 6.6, mean SSI score 2.4.  The Sepsis Six process was not formally 
documented in any case, although 1 patient did have formal documentation of 
assessment of organ dysfunction.  No patient had a complete bundle delivered, 
although 1 patient who triggered on admission had all elements with the 
exception of blood cultures performed within 1 hour.  No blood cultures were 
taken from this patient. 
 Median (mins) Mean (mins) % Completion 
Oxygen 10 6.6 58.3% 
IV Fluids 2.5 30.5 75% 
Blood Cultures -82.5 -281.3 33.3% 
IV Antibiotics -400 -446.3 41.7% 
Lactate 11 -34.5 33.3% 
Full Blood Count 17.5 -52.4 58.3% 
Accurate Urine Output 0 57.5 25.0% 
Table 3-20 – Element completion (Sepsis6 late) 
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Figure 3-12 – Boxplot of time to element completion (Sepsis6 late) 
 
 App Introduction (early) 3.3.4
18 of 193 patients triggered Sepsis Six during this period.  Mean NEWS score for 
these patients was 5.7, mean SSI score was 1.9.  Only 1 patient had Sepsis Six 
documented in their notes but it was not this patient who was the sole patient 
so far to have a complete Sepsis Six bundle.  No patients had formal assessment 
of organ dysfunction. 
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 Median (mins) Mean (mins) % Completion 
Oxygen 9.5 -20 66.7% 
IV Fluids -162.5 -225.6 83.3% 
Blood Cultures -40 -108.3 33.3% 
IV Antibiotics -15 -98.9 50.0% 
Lactate -22.5 -102.5 44.4% 
Full Blood Count 32 -73.9 55.6% 
Accurate Urine Output 15 -62 38.9% 
Table 3-21 – Element completion (App early) 
 
Figure 3-13 – Boxplot of time to element completion (App early) 
 
 App Introduction (late) 3.3.5
14 of 175 patients triggered Sepsis Six.  Of these 11 were unique – one patient 
with pyelonephritis triggered on days 0, 1 and 2, another patient with biliary 
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sepsis triggered on days 0 and 3.  Mean NEWS score was 6.2 and mean SSI score 
2.3.  Sepsis Six was formally documented in 3 cases and 2 patients had a 
complete bundle delivered.  Organ dysfunction was not formally assessed in any 
cases. 
 Median (mins) Mean (mins) % Completion 
Oxygen -30 -231 71.4% 
IV Fluids -995 -1020 92.9% 
Blood Cultures -30 -266 57.1% 
IV Antibiotics -130 -490.1 35.7% 
Lactate -2.5 -76.7 42.9% 
Full Blood Count 45 31.6 57.1% 
Accurate Urine Output -560 -716 35.7% 
Table 3-22 – Element completion (app late) 
 
Figure 3-14 – Boxplot of time to element completion (App late) 
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 Poster Promotion (early) 3.3.6
9 of 159 patients triggered Sepsis Six during this period.  Mean NEWS score was 7 
and mean SSI score at trigger was 2.8.  There was some form of Sepsis Six 
documentation in 3 patients.  Organ dysfunction was formally assessed in 2 
patients.  There were no complete Sepsis Six bundles delivered. 
 Median (mins) Mean (mins) % Completion 
Oxygen -50 -17.5 33.3% 
IV Fluids -240 -550.4 88.9% 
Blood Cultures 55 -395.4 22.2% 
IV Antibiotics -45 -362.2 55.6% 
Lactate 33 62.3 44.4% 
Full Blood Count 30 -144.8 55.6% 
Accurate Urine Output -100 -71.7 22.2% 
Table 3-23 – Element completion (Poster early) 
 
Figure 3-15 – Boxplot of time to element completion (Poster early) 
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 Poster Promotion (late) 3.3.7
Only 6 of 164 patients in this period triggered Sepsis Six.  Mean NEWS score was 
6.8, mean SSI score was 3.  Sepsis Six was documented in 3 of the 6 patients and 
4 had organ dysfunction assessed.  Despite this seemingly impressive 
performance, only 1 patient had a full Sepsis Six bundle delivered. 
 Median (mins) Mean (mins) % Completion 
Oxygen -184 -198 66.7% 
IV Fluids -152.5 -411.2 100% 
Blood Cultures -127.5 -127.5 33.3% 
IV Antibiotics -247.5 -553.7 66.7% 
Lactate 22.5 111.3 50.0% 
Full Blood Count -182 -426.5 50% 
Accurate Urine Output -167 -353.4 83.3% 
Table 3-24 – Element completion (Poster late) 
 
Figure 3-16 – Boxplot of time to element completion (Poster late) 
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 Trends 3.3.8
Time of admission and sepsis trigger 
The majority of admissions either occurred outwith the normal 9am to 5pm 
working day (Table 3-25) or at weekends (Table 3-26).  The time at which 
patients triggered was a little more balanced (Table 3-27, Table 3-28), although 
2 periods (“Sepsis Six fatigue” and “App fatigue”) had almost all of their triggers 
occur out of hours. 
 
 Day / Night Admission Total 
D N 
Audit Period 
Pre-Sepsis Six 3 12 15 
Sepsis Six introduced 4 9 13 
Sepsis Six fatigue 2 10 12 
App introduced 7 11 18 
App fatigue 4 10 14 
App + poster 3 6 9 
Poster fatigue 3 3 6 
Total 26 61 87 
Table 3-25 – Time of admission (day vs. night) 
 
 Out of Hours Admission Total 
N Y 
Audit Period 
Pre-Sepsis Six 1 14 15 
Sepsis Six introduced 4 9 13 
Sepsis Six fatigue 2 10 12 
App introduced 3 15 18 
App fatigue 4 10 14 
App + poster 3 6 9 
Poster fatigue 2 4 6 
Total 19 68 87 
Table 3-26 – Time of admission (weekday daytime vs. overnight or weekend) 
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 Day / Night Trigger Total 
D N 
Audit Period 
Pre-Sepsis Six 7 8 15 
Sepsis Six introduced 6 7 13 
Sepsis Six fatigue 1 11 12 
App introduced 11 7 18 
App fatigue 3 11 14 
App + poster 4 5 9 
Poster fatigue 3 3 6 
Total 35 52 87 
Table 3-27 – Time of trigger (day vs. night) 
 
 Out of Hours Trigger Total 
N Y 
Audit Period 
Pre-Sepsis Six 4 11 15 
Sepsis Six introduced 5 8 13 
Sepsis Six fatigue 1 11 12 
App introduced 6 12 18 
App fatigue 3 11 14 
App + poster 4 5 9 
Poster fatigue 1 5 6 
Total 24 63 87 
Table 3-28 – Time of trigger (weekday daytime vs. overnight or weekend) 
There was no significant difference in mean time to completion across the 
elements with the exception of the time between blood cultures and sepsis 
trigger.  For an out of hours admission blood cultures were taken an average of 
94.5 minutes prior to trigger.  For an admission with normal hours during the 
week, they were obtained 180.4 minutes prior (p=0.11, Chi-square).  As this is 
the only significant difference it may be due to chance but, if one bears in mind 
the significant delays from admission to triggering Sepsis Six, this actually 
suggests blood cultures are being taken more promptly as part of the standard 
process for daytime admissions.  The level of staff availability between day and 
night is likely to be a factor here. 
Chapter 3  86 
Admission to sepsis trigger 
Time from admission to trigger was not significantly different between the audit 
periods (p=0.67, one-way ANOVA).  Some outliers are seen in 3 of the audit 
periods but, in general, most patients who are going to trigger Sepsis Six do so 
within the first 36 hours of admission (Figure 3-17, Table 3-29). 
 
Figure 3-17 – Boxplot of time from admission to sepsis trigger (minutes) 
 Pre-
Sepsis Six 
Sepsis6 
(early) 
Sepsis6 
(late) 
App 
(early) 
App 
(late) 
Poster 
(early) 
Poster 
(late) 
Mean 
time to 
trigger 
(hours) 
23.5 25.2 32.6 14.7 20.2 13.1 9.8 
Table 3-29 – Mean time in hours from admission to sepsis trigger 
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Element Completion 
The trends for completion of all elements of Sepsis Six are shown in Figure 3-18.   
 
Figure 3-18 – Element completion over all audit periods 
There is significant variation in element completion from one period to the next.  
Some, including IV fluids and measurement of lactate, do seem to have an 
upward trend.  However no element showed a statistically significant difference 
between baseline and the final audit period (Table 3-30). 
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 Levene's Test for 
Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
O2 
Equal variances 
assumed 
.50 .488 -.079 19 .938 
Equal variances 
not assumed 
  -.073 8.05 .943 
IV fluids 
Equal variances 
assumed 
8.38 .009 -1.14 19 .270 
Equal variances 
not assumed 
  -1.45 16.63 .165 
Blood cultures 
Equal variances 
assumed 
.007 .933 -.08 19 .935 
Equal variances 
not assumed 
  -.08 9.24 .936 
Antibiotics 
Equal variances 
assumed 
.003 .954 -.14 19 .890 
Equal variances 
not assumed 
  -.14 8.69 .895 
Lactate valid 
Equal variances 
assumed 
.77 .390 -1.13 19 .274 
Equal variances 
not assumed 
  -1.05 8.16 .322 
FBC valid 
Equal variances 
assumed 
.12 .736 -.35 19 .728 
Equal variances 
not assumed 
  -.35 9.21 .733 
Urine output 
Equal variances 
assumed 
1.87 .188 -1.34 19 .195 
Equal variances 
not assumed 
  -1.44 10.88 .177 
Table 3-30 – Element completion baseline versus poster (late) period 
Small sample size will play a major factor.  With so few cases of sepsis in the 
final 2 audit periods, to achieve statistical significance would be difficult.  
Anything doing so may well be spurious.  The data collected as part of the 
Scottish Patient Safety Programme (SPSP) aims to record 20 cases per month to 
give a better chance of showing reliable trends.  This is, of course, dependent on 
case incidence and ascertainment. 
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With median time to element completion, there is again no clear trend for any 
of the elements across any time periods (Figure 3-19).  The majority of elements 
are being delivered in advance of the sepsis trigger throughout all periods.  This 
is due to patients consistently not triggering Sepsis Six until many hours after 
admission.  The lowest mean time from admission to trigger was 9.8 hours (Table 
3-29).  In 4 of the periods it was in excess of 20 hours.  As many Sepsis Six 
elements comprise part of standard surgical care, one should expect that they 
should be instituted before crisis point is reached.  Sepsis Six is poor at taking 
account of this and works best where the patient is already septic at hospital 
admission and one is starting with a clean sheet. 
 
Figure 3-19 – Median time to element completion across all periods 
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 Focus Group for Foundation Doctors - Feedback on 3.3.9
Guidelines and App Research 
In June 2013 a small focus group was held with six of the Foundation doctors 
who had worked in the surgical department between August 2012 and August 
2013.  It had become clear that the app was not the simple answer to the 
problem of guideline compliance that had been hoped for.  This student wished 
to know what the barriers had been for this particular group of doctors. 
A summary of their responses is below: 
Sepsis Six 
What stopped you following Sepsis Six guidelines accurately? 
Didn’t know they existed  Didn’t think they applied to my patients  
Thought I knew them already 2 Couldn’t be bothered  
No obvious penalty for non-
compliance 1 
Time pressure – no time to look things 
up 1 
Specifically told not to follow these 
guidelines  
Guidelines not part of the culture of the 
ward 1 
Couldn’t get help to fulfil all 
elements of package in <1 hour 4 Couldn’t access the guidelines  
 
Specific comments:  
• “I’d do it if a senior told me specifically” 
• “If I knew there was a penalty for non-compliance I’d try harder” 
• Need a better Sepsis Six trolley with everything fully-stocked and 
accessible, like in medicine. 
• Desire for the ward nurses to tell them immediately that a patient has 
triggered NEWS >4 and that they’ve started the one hour egg-timer – 
requirement of pressure to complete was repeatedly mentioned. 
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Did you use the Sepsis Six App: Y = 3  /   N = 3 
If Yes:       Comments 
How many times did you use it? 
1-3 = 1 
4-6 = 1 
7-10 = 1 
> 10 = 0 
Did you like the App? Y = 2, No answer = 1 
Was it user-friendly? Y = 2, No answer = 1 
Would you use it again? Y = 2, No answer = 1 
Would you recommend it to a colleague? Y = 2, No answer = 1 
Any improvements you’d like to suggest?  
 
 
If No, why not? 
No smartphone  No battery when I needed it  
No septic patients  Forgot App existed 1 
No pockets on clothes so I don’t 
carry my smartphone at work    
Didn’t want to use smartphone in 
presence of patient – in case thought 
unprofessional 
 
Management directive not to use 
smartphones in patient 
environment 
 
Concern that seniors might think I’m 
skiving off if seen using smartphone at 
work 
 
Didn’t think I needed to use it – 
knew guidelines already 1 
Didn’t get app uploaded 
 
1 
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Thromboprophylaxis 
What stopped you following thromboprophylaxis guidelines accurately? 
Didn’t know they existed  Didn’t think they applied to my patients  
Thought I knew them already 4 Couldn’t be bothered  
No obvious penalty for non-compliance  Time pressure – no time to look things 
up 2 
Specifically told not to follow these 
guidelines 
 Guidelines not part of the culture of the 
ward 
 
Couldn’t access the guidelines  Other:   
 
 
Did you use the thromboprophylaxis App: Y = 5  /   N = 1 
If Yes:       Comments 
How many times did you use it? 
1-3 = 1 
4-6 = 2 
7-10 = 1 
> 10 = 1 
Did you like the App? Y = 5 
Was it user-friendly? Y = 5 
Would you use it again? Y = 4, Not sure = 1 
Would you recommend it to a colleague? Y = 4, No answer = 1 
Any improvements you’d like to suggest? No guidelines on extremes of weight – such as 
morbid obesity 
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If No, or not regularly, why not? 
No smartphone  No battery when I needed it  
Never needed to prescribe LMWH or 
AES  Forgot App existed 1 
No pockets on clothes so I don’t carry 
my smartphone at work    
Didn’t want to use smartphone in 
presence of patient – in case thought 
unprofessional 
2 
Management directive not to use 
smartphones in patient environment 1 
Concern that seniors might think I’m 
skiving off if seen using smartphone at 
work 
2 
Didn’t think I needed to use it – knew 
guidelines already 1 Flowchart in medical proforma 1 
94 
4 Discussion 
 Implications of Results 4.1
 Smartphone Ownership and Use for Healthcare 4.1.1
Smartphone ownership decreases with increasing age, especially over the age of 
fifty. As older consultants, less comfortable and familiar with smartphone 
technology, are gradually replaced by a more tech-literate younger generation 
this decline in ownership rates is likely to become less obvious.  Although 
worldwide there is a distinct preference for android-based smartphone 
technology, this is much less pronounced in the medical fraternity and 
frequently the converse, compared with iPhone ownership. Compounding this is 
the unmistakeable brand-loyalty displayed by Apple customers.  Other platforms 
are still very much minor players.  This emphasises the need to support both 
android and iOS platforms with new software. 
It was interesting to see the peak for those using smartphones for clinical care to 
be during the core and specialty trainee years, making them roughly 25-33 years 
of age. This highlights the appreciation that doctors at this stage in their training 
have about their level of knowledge and correlates with published data  (53).  It 
may also reflect the possibility that currently downloadable apps for doctors are 
aimed at those more senior than Foundation Doctors.   
 Thromboprophylaxis 4.1.2
The baseline audit revealed that, contrary to expectation and past experience, 
prescription of LMWH was already done well, leaving limited potential for the 
app to improve on this. The SPSP target for accurate LMWH prescription is 95% 
and RAH surgical department, at baseline, was approaching 90%. Despite this, 
the complacency issue seems to have prevented the app helping to reach this 
target.  
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AES prescribing and actual application of the stockings didn’t change overall. 
Indeed, there was evidence to suggest that the app was not being used; AES 
were being prescribed for patients with clear contraindications. Similarly, dose 
reduction for low bodyweight or poor renal function (on admission) was not 
taking place. Interestingly, the obverse was also true for patients who had been 
transferred from the receiving ward to the general surgical ward; when renal 
function had recovered it took a long time for the for LMWH to be up-titrated on 
the prescription, potentially exposing the patient to greater VTE risk during that 
period (data not included in this body of work).  Unfortunately the app would 
only avert this problem if it were used to calculate LMWH dose for every patient, 
every day.  
It was gratifying to see a modest improvement in the correct prescribing and 
application of AES after initial introduction of the app, albeit this was an 
unsustained phenomenon.  This makes it problematic to determine the 
contribution of the app to this result. 
 Sepsis Six 4.1.3
Out-of-hours triggering 
The majority of Sepsis Six patients were triggering outwith standard working 
hours. Out-of-hours hospitals are run on considerably reduced staffing levels, 
especially covering the wards. This is likely to be a significant contributing 
reason behind failure to complete all elements in one hour, and may explain why 
the majority of doctors in the focus group reported a prime reason for not 
delivering a Sepsis Six bundle correctly was that they couldn’t get help to fulfil 
all elements of package in less than one hour. Targeting of resources to this 
identified gap in service provision may be key to improvement.  
It has become apparent that other health boards in Scotland operate very 
different methods of response to a Sepsis Six trigger. In the neighbouring 
hospitals of Ayrshire and Arran health board it is made clear at the annual 
hospital induction that non-compliance with Sepsis Six implementation will be 
taken very seriously, with repercussions for those involved. At any point of the 
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day and or night the duty ANP and the responsible FY1 are paged when a patient 
is recorded as having an elevated NEWS score >4. They are required to respond 
and review the patient within fifteen minutes and, if the patient is confirmed to 
be septic, institute the Sepsis Six bundle within the following forty-five minutes.  
The ANP also comes back within four hours to review the patient and check a 
repeat lactate level, to verify clinical improvement.  Assessment of organ 
dysfunction, however, is not done so flawlessly. The Sepsis Six process, and the 
timings thereof, is strictly audited by the ANP team, with feedback given to 
departmental managers as well as the ward nurses and junior doctors about 
good, as well as poor, performance. Using these methods, Ayrshire and Arran 
routinely achieve >95% compliance, similar to the MAU at RAH. 
During the period of research ANPs at RAH only covered the surgical wards 
overnight and at weekends.  This was distinct to the medical wards where they 
had a twenty-four hour presence. If GGC were to employ the Ayrshire and Arran 
dual-pronged response to a Sepsis Six trigger, it is not unreasonable to anticipate 
a sharp improvement in Sepsis Six bundle compliance. This would, naturally, 
have cost implications that would have to be taken into consideration. 
Differences between medical and surgical patients 
Sepsis Six works well in the medical directorate as, at presentation, most 
patients with infection already manifest signs of systemic sepsis and the bundle 
of care can be delivered immediately, between the start of the egg timer and 
the buzzer alarming at sixty minutes. Analysis of the time from admission to 
time of trigger in these surgical patients revealed a median difference of 
approximately twenty-four hours. This serves to explain the seemingly pre-
emptive antibiotics, fluids and blood tests in a lot of patients that were started 
for localised infection on admission but evolved into systemic sepsis thereafter. 
The very different behaviour of medical and surgical patients suggests they 
should not be treated as a homogenous group of patients, and may be much 
better served being recognised as two distinct entities. 
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Complete Sepsis Six bundles 
Despite Sepsis Six having been introduced almost a year previously, and despite 
the breadth of the modalities employed to try to encourage engagement, the 
frequency of bundle completion remained dismal. Some complete bundles were 
delivered following deployment of the app, but it is difficult to determine if this 
is primarily a success for the app or part of the on-going process of Sepsis Six 
integrating into the fabric of the surgical receiving ward. 
Assessment of organ dysfunction 
A total of eighty-seven patients were identified as being septic during the whole 
research project. Of these, only seven had documented evidence that they had 
been assessed for organ dysfunction, one patient being assessed following initial 
introduction of Sepsis Six and six following the “back-to-basics” poster 
campaign. It seems that while the concept of the one-hour resuscitation bundle 
has been slowly seeping into the fabric of the surgical receiving ward, the 
patients were not routinely being followed-up to determine if they had “simple” 
sepsis or whether they were potentially considerably more unwell. While an 
elevated lactate can help discriminate, assessment for organ dysfunction is vital 
to facilitate earlier recognition of the patient requiring early involvement of 
critical care personnel. 
 Barriers to App Usage by Junior Doctors 4.2
 Confidentiality, security and public perception 4.2.1
The surgical junior doctors may have not wished to use these app in the clinical 
setting due to concerns about confidentiality and how they would be perceived 
by patients and other colleagues (although this was cited considerably more 
frequently at the Focus Group (2/6, 33%) than in the initial SurveyMonkey 
questionnaire (4/180, 2%). This is supported by work in Australia which found 
that the general public was “generally more accepting of the internet being used 
during clinical practice than apps”  (67) as well as the Imperial College 
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microbiology team, when they devised and implemented their antibiotic 
prescribing app  (54). 
It was further suggested that Foundation doctors may not yet have got into the 
mindset of taking work home. They still differentiated into black and white what 
they did in each environment. Smartphones might be considered a “home” thing 
and not associated with work. 
 Accuracy of apps 4.2.2
The importance of the accuracy of the data contained in and results produced by 
a smartphone app cannot be emphasised enough.  Although this was not detailed 
as a concern in the small focus group, it was highlighted by more senior 
respondents in the initial survey.  Keeping apps updated with the most current 
guidelines and recommendations is a very real problem, particularly with native 
apps, as it relies on the user realising they have to regularly manually update 
the software and applications on each device they own  (54). 
 Complacency 4.2.3
Fundamentally there were major complacency issues surrounding these 
seemingly simple algorithms, candidly confirmed in the focus group. Both VTE 
prophylaxis and Sepsis Six are major SPSP targets. Despite them being so 
important, the Foundation Doctors thought they knew the guidelines well-
enough that, when pressed for time, it wasn’t worth the effort to open an app 
to confirm this; this body of research would refute that notion. 
The two year UK Foundation Programme takes doctors straight from Medical 
School and potentially as young as twenty two years of age.  As new FY1s they 
have insight into their lack of knowledge and are receptive to new information.  
It is well recognised that this situation changes quickly and insight is lost 
disproportionate to expansion in knowledge.  The apps were tested towards end 
of the FY1 year when many of the surgical doctors would have entered this 
second, recognised, phase of learning and this may have been a mitigating factor 
in both overall guideline compliance and app utilisation.  By the time of entering 
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core and, particularly, specialty training doctors have entered a third phase of 
learning and know that they have some knowledge but are keen to expand it and 
they look for opportunities to do so. 
 Inaccurate NEWS recording 4.2.4
There were on-going issues with identification and documentation of correct 
NEWS score by the ward nurses. This was critical as, without identifying the 
potentially septic patients, care couldn’t be delivered. Analysis of the NEWS 
charts (Appendix 7) revealed that documentation error was the greater problem; 
“dots” to mark parameters were not being marked accurately and values were 
being written in the wrong rows, mainly for oxygen saturations. The colour-
coding is designed to assist the brain in calculating the total score. If abnormal 
values were erroneously being noted in a “white” area, they were not 
infrequently being missed and scored as 0, when potentially the score might 
have been 2, for example. It was also brought into standard practice that the 
nurses routinely perform bedside blood glucose measurement when the NEWS 
was >4, to permit proper sepsis screening. 
This issue of incorrect appreciation of the severity of physiological derangement 
due to poor “totting up” of the individual elements of the NEWS score is well 
recognised.  Attempts have been made to address this problem by providing an 
electronic solution: the NHS Education for Scotland (NES) working party released 
an iPhone app in June 2013 with NEWS calculation built in. Identification of 
deranged physiology led to advice to screen for sepsis and, if positive for the 
systemic inflammatory response, the user was taken into the Sepsis Six screen. 
The logic for this NES app was donated from this research project – as can be 
seen from the manifest similarity between the two apps. 
 Leadership and motivation 4.2.5
Williams et al (15) suggested that clear advice from a senior figure/group and 
direct motivation to adhere to guidelines was the most likely factor influencing 
compliance. The top-down, hands-on, highly visible and incentivised 
management style of the acute physicians at the RAH emulates this and is likely 
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to be the reason for markedly differing Sepsis Six bundle completion rates 
between MAU and surgery. This constant presence on the ward is not 
reproducible in a surgical environment with current consultant working patterns. 
If this is consistently shown to be the only factor likely to increase motivation 
and compliance, then it may be that working patterns need to be reconsidered. 
One factor that has been proven to be beneficial in nursing infrastructure is 
having “champions” for various identified areas. At present a trained nurse or 
healthcare assistant is highlighted as a champion for issues such as pressure 
sores, hand hygiene, nutrition etc. The champion’s role is to promote and 
encourage good practice and protocol compliance for their niche area, and act 
as a peer mentor and example of best practice to colleagues. There would 
certainly be a role for a Sepsis Six champion in the surgical wards at RAH. This 
would hopefully encourage nurses to recognise septic patients and be 
empowered to implement the Sepsis Six bundle and inform junior doctors to 
fulfil their elements in a timely fashion. 
 Commercial Apps Released During Study Period 4.3
 Thromboprophylaxis 4.3.1
Four apps aimed at clinicians have been released since the start of this research 
project. They are all commercial projects, one of them only being available in 
Spain. This particular app, CLX Caprini, is produced by Sanofi and appears to be 
the successor to the French Clexane app.  It was released in April 2013, and can 
be downloaded free-of-charge. 
Of the other three apps, one costs £6.99 to download and was released in March 
2014. It contains no mention of applying for, or indeed needing FDA/MHRA 
approval for the app, despite giving prescribing advice.  This is in contrast to an 
app released in October 2013 that is free to download and contains a carefully 
worded disclaimer and makes no attempt to provide prescribing information.   
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 Sepsis Six 4.3.2
The first Sepsis Six app became available to download in December 2012.  This 
was marketed by the “Survive Sepsis” campaign and contained an interactive 
sepsis screening tool and an interactive “tick-sheet” for documenting completion 
of each element of the bundle.  It also guided the user through the escalating 
cascade of severity of sepsis, ensuring that organ function was evaluated.  Initial 
versions were not particularly user-friendly and updates during 2013 have 
improved on the original app. 
The “Keep calm and do the Sepsis Six” app was launched in January 2013 but 
was non-interactive and had limited functionality, although it proved popular 
due to its moniker.  Later that year the official NHS Scotland app was released in 
June 2013.  There was significant collaboration at a design level between this 
project and the team developing that app. 
 Limitations of this project 4.4
A problem found to be unique to owners of android phones was that of having 
out-dated software. If they hadn’t updated their operating system for several 
versions it proved impossible to deploy the app onto these smartphones. This 
situation simply wasn’t encountered in iPhone users as uptake of each update is 
so rapid. Interestingly Charani et al found the very same problem  (54). 
The patient-safety topics of thromboprophylaxis and sepsis were perceived as 
too simple by many FY doctors to make them worthy of using an app for. This 
was despite clear evidence that there was room for improvement. This partial 
app adoption made it difficult to extract change related to app introduction 
from other potential sources for improvement. 
Despite rigorous examination of all patient casenotes during the two-week audit 
cycles, there was overall a low number of septic patients in this project, 
especially in the last two audit cycles. This makes significance difficult to 
achieve or prove. The thromboprophylaxis project was slightly confounded by 
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the ubiquitous problem of missing data, although it did not prevent meaningful 
conclusions being drawn for most areas. 
The annual junior doctor changeover took place during the first week of August 
2013. Although the incoming FY1 doctors had spent six weeks shadowing during 
May 2013, and also spent the seven days prior to taking up post as 
supernumerary doctors on the wards, this was not the same cohort as the two 
preceding audit cycles. It had proved logistically impossible to undertake the 
final audit cycles prior to the changeover due to the sheer number of 
interventions that had taken place over the year, especially with two audit 
cycles after each intervention.  To minimise the impact this might have on data 
collection, each app was deployed onto the smartphones of the incoming doctors 
while they were undertaking their shadowing period in order that they could be 
as familiar with using it as their outgoing counterparts. 
 Conclusions 4.5
With on-going developments and rapid progress towards a paperless society and 
healthcare being provided electronically, it is inevitable that the use of 
smartphone apps for direct patient care will become more familiar and, indeed, 
commonplace.  Certainly doctors surveyed for this project have already 
embraced smartphone technology and indicated enthusiasm, in principle, for 
guideline apps such as those tested here. 
As hypothesised, the addition of a smartphone app for relatively simple 
guidelines did not affect compliance rates but it proved impossible during this 
brief research period to test the hypothesis on a more complex set of guidelines.  
Fatigue was difficult to assess due to low numbers and conclusions relating to 
this cannot be drawn.  While it is disappointing not to be able to prove the 
importance and benefit of smartphone apps for direct patient care they are 
likely to continue to be a growth market. 
It is clear from the work undertaken here that basic principles of visible and 
omnipresent top-down leadership will always be required to support change, 
adoption of new ideas and sustained compliance with them.  
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 Future Directions 4.6
 Junior Doctor Education 4.6.1
It is clear that education of junior doctors on the wards is paramount to 
adherence with protocols. Formal, structured education sessions about both 
thromboprophylaxis and Sepsis 6, coupled with interactive tutored sessions 
about the apps, could be instituted at the start of each new cycle of junior 
doctors. These would emphasise the importance of these aspects of patient 
safety and the tools available to facilitate protocol compliance. It would be 
interesting and useful to conduct a full audit cycle both before and at the two 
points after this enhanced education session and see if a more focussed 
educational input would improve guideline compliance. 
 Electronic Patient Record 4.6.2
The initial phase of this project illustrated how ubiquitous smartphones are 
among doctors of all ages, particularly younger, more junior colleagues.  It is 
time to capitalise on this and move resources to this medium and away from the 
antiquity of paper and standard computers.  The future of secondary care is 
electronic and paper-free, with integrated patient observations, lab results, 
radiology and prescribing. Wholly electronic care provision already exists in 
some UK hospitals and more widely across North America, using secure tablets 
linked in to encrypted hospital Wi-Fi.  Such a project is currently being trialled 
in the neighbouring Ayrshire and Arran health board. 
The advent of the electronic patient record (EPR) and electronic prescribing 
should facilitate timely prescription of thromboprophylaxis, especially if 
safeguards are built in to prevent moving on from the VTE prophylaxis screen 
until either LMWH and AES have been prescribed or contraindications 
documented.  
Medicines reconciliation forms (both paper-based and electronic) will play a role 
in encouraging appropriate prescribing of VTE prophylaxis. These are completed 
by junior medical staff and verified by a ward pharmacist, ensuring safe and 
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timely confirmation and prescription of medications already taken by the 
patient. Medicines reconciliation forms have already been built in to paper-
based admissions proformas (see Chapter 1.1.2) and include a 
thromboprophylaxis section to ensure the admitting doctor is reminded of the 
importance of assessing risk and making an appropriate prescription. As 
discussed in Chapter 1, the current unwieldy nature of these paper-based 
thromboprophylaxis flow-charts inhibits compliance and hopefully moving to an 
electronic format will improve this problem. 
 Colorectal Polyp Surveillance App 4.6.3
An app to aid the calculation of correct surveillance interval for colorectal 
polyps is currently being developed. These polyps are pre-cancerous growths in 
the large bowel that can be detected visually during a colonoscopy. Once 
removed, the risk of malignant transformation to a bowel cancer is obviated. 
However, the risk of significant injury to the bowel is one in one thousand for a 
diagnostic colonoscopy, rising to one in fifty for removal of a large polyp. These 
two factors compete to determine the surveillance interval between tests, 
ensuring it remains as safe as possible while minimising the likelihood of an 
interval cancer.  A useful benefit of ensuring the correct surveillance interval 
will be to decrease the waiting list for colonoscopy. The easy default position, if 
one is unsure, is to continue to survey patients ad infinitum, and more 
frequently than indicated, rather than risk missing a cancer. This is poor 
practice and detrimental to a service with finite resources. 
An app is likely to be of great use and interest to those involved in polyp 
surveillance as national guidelines from the British Society of Gastroenterology 
(BSG)  (82), while being practical, can bewilder the novice.  This app will follow 
the BSG guidelines but use their algorithms to tailor a surveillance interval to a 
particular patient, taking into account their genetic predisposition (if known), 
size and number and histology of previous polyps, from all previous 
colonoscopies, as well as their age.   
It is immediately evident that this app is quite different from the simple ones 
trialled in this project. The complexity of the decision-making will make a 
Chapter 4  105 
supporting app enticing, particularly as it may permit streamlining of the process 
leading to appointment to follow-up colonoscopy. At present, nurse endoscopists 
can vet a patient direct to test, undertake the actual colonoscopy but then the 
decision-making regarding surveillance interval is deferred to a responsible 
consultant (either surgeon or gastroenterologist). If such an app as is proposed 
can be made to work, this will allow the endoscopist to calculate the 
appropriate surveillance interval at the end of the procedure, cutting out the 
consultant “middle-man” and any attendant delays appointment delays. It would 
also lend itself to the running of an autonomous nurse-led polyp clinic, where 
patients could be seen regarding their histopathology results, thereby relieving 
pressure of return appointments to the consultant-led colorectal clinic. These 
anticipated benefits would have a significant positive impact on the provision of 
surgical services. 
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Appendix 1 SurveyMonkey Questions 
Questions Dropdown answers 
What is your grade? Consultant, Specialty Doctor/SG/AS, 
ST3-8/LAT3-8/SpR, CT/LAT1-2, FY1, 
FY2,  
What is your gender? Male, Female 
What is your specialty? Medical Specialties, General Surgery, 
Orthopaedics, Surgical Subspecialties 
(ENT/ophthalmology/urology...), 
Psychiatry, Anaesthetics, Radiology, 
Emergency Medicine, Obstetrics & 
Gynaecology, Pathology/Laboratory 
Medicine, General Practice, Paediatrics 
Which site do you work at most? RAH, IRH, VoL 
What age are you? 20-29, 30-39, 40-49, 50-59, 60 or older 
Do you own a smartphone? Yes, No 
If NO - Although you don't own a 
smartphone now, would you consider 
using one in the future? 
Yes, No, Don’t know 
What make of Smartphone do you use? iPhone, Samsung, Nokia, HTC, 
Blackberry, LG, Sony,  
Do you use your Smartphone for 
patient care? 
Yes, No 
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In what way do you use your 
Smartphone for patient care?  
(freetext) 
Do you have any medical-related 
Smartphone Apps? 
Yes, No 
Which medical Apps do you own? (freetext) 
Do you use these medical Apps 
regularly? 
Yes, No 
Which are the medical Apps you use 
most regularly? 
(freetext) 
Does the price of Apps influence your 
decision about buying them? 
Yes, No 
Is there a maximum price you’d pay for 
a medical-related App? 
FREE, £0.49, £0.99, £1.99, £4.99, 
£9.99, No maximum price threshold if 
App is “worth it” 
Would you be interested in Apps 
specifically-designed for patient care 
that use local GGC and/or national 
guidelines? 
Yes, No 
What price would you be prepared to 
pay for such Apps? 
FREE, £0.49, £0.99, £1.99, Other 
(please specify) 
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Appendix 2 Thromboprophylaxis risk assessment 
 
Reproduced, courtesy of Dr C Foster, Lead Clinician for Thromboprophylaxis, 
RAH. 
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Appendix 3 Key to levels of evidence and grading 
of recommendations  (1) 
3.1 Levels of evidence  
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a 
very low risk of bias 
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low 
risk of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort studies 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is 
causal 
2+ Well conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship 
is causal 
2- Case control or cohort studies with a high risk of confounding or bias and 
a significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
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3.2 Grades of recommendation 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and 
directly applicable to the target population;  
or 
A body of evidence consisting principally of studies rated as 1+, directly 
applicable to the target population, and demonstrating overall 
consistency of results 
B A body of evidence including studies rated as 2++, directly applicable to 
the target population, and demonstrating overall consistency of results;  
or 
Extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+, directly applicable to 
the target population and demonstrating overall consistency of results;  
or 
Extrapolated evidence from studies rated as 2++ 
D Evidence level 3 or 4; or 
Extrapolated evidence from studies rated as 2+ 
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Appendix 4 Sepsis Six data collection proforma 
 
  112 
Appendix 5 Systemic Inflammatory Response and 
Sepsis 
5.1 SIRS 
SIRS is considered to be present when patients have two or more of the following 
clinical findings (38): 
• Body temperature > 38°C or < 36°C 
• Heart rate > 90/min 
• Hyperventilation evidenced by respiratory rate > 20/min, or PaCO2 < 32 
mmHg (4.3 kPa) 
• White blood cell count > 12,000 cells/µL or < 4,000/ µL 
Levy’s group also noted that two further features were frequently associated 
with septic patients. These features have since been incorporated into the list of 
criteria for diagnosis of SIRS, making a total of six (40): 
• Acute confusion or reduced conscious level 
• Blood glucose > 7.7mmol/L (unless diabetic) 
 
5.2 Sepsis 
SIRS plus documented or strongly suspected infection 
5.3 Severe sepsis 
Sepsis plus sepsis-induced organ dysfunction or tissue hypoperfusion (defined as 
infection-induced hypotension, elevated lactate, or oliguria. Abnormalities can 
also be seen in other parameters) 
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5.4 Septic shock 
Severe sepsis with sepsis-induced hypotension that persists despite adequate 
fluid resuscitation – usually requiring inotropic or vasopressor support. 
Sepsis-induced hypotension is defined as a systolic blood pressure (SBP) < 90mm 
Hg or mean arterial pressure (MAP) < 70mm Hg or a SBP decrease > 40mm Hg or 
less than two standard deviations below normal for age in the absence of other 
causes of hypotension. 
In the 2012 update of the Surviving Sepsis Campaign (45), a distinction is made 
between septic shock (sepsis-induced hypotension which persists despite 
adequate fluid resuscitation) and sepsis-induced tissue hypoperfusion which adds 
elevated lactate and oliguria to hypotension as markers of sepsis severity. 
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Appendix 6 Surviving Sepsis Campaign Guidelines 
6.1 The Surviving Sepsis Campaign 6-hour 
resuscitation bundle 
• Measure serum lactate  
• Obtain blood cultures prior to antibiotic administration 
• From the time of presentation, broad-spectrum antibiotics to be given 
within 1 hour 
• Source of infection to be identified and drained within 6 hours 
• In the event of hypotension and/or lactate >4mmol/L (36mg/dl): 
o Deliver an initial minimum of 20 ml/kg of crystalloid (or colloid 
equivalent)  
o Give vasopressors for hypotension not responding to initial fluid 
resuscitation to maintain mean arterial pressure (MAP) > 65 mm Hg 
• In the event of persistent arterial hypotension despite volume 
resuscitation (septic shock) and/or initial lactate >4 mmol/l (36 mg/dl): 
o Achieve central venous pressure (CVP) of >8 mm Hg 
o Achieve central venous oxygen saturation (ScvO2) >70%  
This was initially defined in 2008 (42) and subsequently updated in 2012 (45). 
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Appendix 7 National Early Warning Score 
Source: www.rcplondon.ac.uk/resources/national-early-warning-score-news  
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Appendix 8 Sepsis Six box contents 
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Appendix 9 Thromboprophylaxis App Poster for 
the Wards 
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Appendix 10  Pre-existing Sepsis Six Documentation 
  
Sepsis Six poster utilised by the Acute Physicians at RAH from 2012. 
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Sepsis Six sticker utilised by the Acute Physicians at RAH from 2012. 
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